Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX

Session Summary: Hypertrophic and infiltrative cardiomyopathies are often underrecognized. There has been increasing understanding of HCM and cardiac amyloidosis with rapid development of diagnostic modalities and treatment strategies. This symposium will begin with a case and then review recent advances, highlighting key therapeutics that are available and being developed. The role of heart transplant and advanced therapies in these entities will be outlined.

Chairs: Jignesh K. Patel, MD, PhD and Marta Farrero Torres, MD
 

7:00 AM	CASE PRESENTATION of HCM: Gasping and Dizzy - Please Help! Imad Hussain, MD, Houston Methodist Hosp, Houston, TX, USA
7:05 AM	Veni, Vidi, Vici: Pathophysiology and Therapeutic Options in Hypertrophic Cardiomyopathy Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
7:25 AM	CASE PRESENTATION of Cardiac Amyloidosis: I Can't Breathe and My Tongue is Too Big! Song Li, MD, University of Washington, Seattle, WA, USA
7:30 AM	Double Double Toil and Trouble: Physiology and Therapeutic Options for Cardiac Amyloidosis Margot Davis, MD, University of British Columbia, Vancouver, BC, Canada
7:50 AM	10-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: BSTR, PHARM

Session Summary: As the number of older transplant patients continues to grow it becomes more important to understand age-associated immune changes, which may influence the impact of immunosuppression. Older lung transplant patients experience increased rates of infection, malignancy, and death, but decreased rates of rejection, suggesting over immune suppression. Yet at the same time, older transplant recipients experience increased levels of inflammation.

Chairs: Jonathan P. Singer, MD, MS and Hanneke Kwakkel-van Erp, MD, PhD
 

7:00 AM	Frailty and Pro-Inflammatory Cytokines: Potential Biomarkers for Poor Outcomes? Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA
7:15 AM	Q&A
7:20 AM	Immune Senescence and Transplantation: Balance Between Infection and Rejection Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA
7:35 AM	Q&A
7:40 AM	Challenges in Medication Administration in Older Transplant Patients Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland
7:55 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: MCS
Secondary Audience: HF/HTX

Session Summary: The aim of this symposium is to update attendees on cutting edge techniques and experiences in the realm of ECMO, related both to BTT and non-BTT populations. Therapies and strategies that used to seem very isolated (mobilizing on ECMO, etc.) are likely more mainstream than previously thought. An understanding of the data and outcomes may lead to expanded international adoption of some useful practices.

Chairs: Feras Khaliel, MD, PhD and Ivan Knezevic, MD
 

7:00 AM	Pressure Volume Loops: What Insight Can They Give Us on Device Strategy? Navin K. Kapur, MD, Tufts Medical Center, Boston, MA, USA
7:15 AM	Q&A
7:20 AM	The Future of ECMO: It’s All About Hemocompatibility Omar Saeed, MD, Montefiore Medical Center, Bronx, NY, USA
7:35 AM	Q&A
7:40 AM	When the Bridge Has Termites: The Impact of ECMO-Related Infections on Post-Transplant Outcomes in Bridged Patients Priya Nair, MD, St Vincent's Hospital, Sydney, Australia
7:55 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PATH
Secondary Audiences: BSTR, LF/LTX, PEDS

Session Summary: Clinical and pathologic definitions for chronic rejection in lung transplantation - antibody-mediated rejection (AMR) and chronic lung allograft dysfunction (CLAD) - have undergone rapid changes over the past decade. This session will provide an update on the two major areas of discussion and acquisition over the recent years (AMR, CLAD) and potential areas for future development.

Chairs: Monique Malouf, MD and Desley Neil, FRCPath
 

7:00 AM	Clinical Review of Antibody Mediated Rejection and Chronic Lung Allograft Dysfunction Navin K. Kapur, MD, Tufts Medical Center, Boston, MA, USA
7:15 AM	Pathology of Antibody Mediated Rejection Fiorella Calabrese, MD, University of Padua, Padua, Italy
7:30 AM	Pathology of Chronic Lung Allograft Dysfunction David M. Hwang, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
7:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PH
Secondary Audience: CTEPH

Session Summary: Exercise testing plays a key role in the management of PAH and CTEPH, diseases with exercise-induced symptoms. In contrast with 6MWD, CPET provides unique insights in the pathophysiology of PAH and CTEPH. In addition, the role of key variables derived from CPET on outcome may be useful in assessing treatment efficacy in clinical practice and maybe clinical trials. This symposium will review the various aspects of this technique, from pathophysiology to outcome prediction.

Chairs: Marco Guazzi, MD, PhD and William Auger, MD
 

7:00 AM	Bicycle Race: Basic Principles of CPET Lisa Mielniczuk, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada
7:15 AM	Under Pressure: CPET in PAH and CTEPH Marco Guazzi, MD, PhD, IRCCS Pol San Donato, Milan, Italy
7:30 AM	Don’t Stop Me Now: CPET to Predict Outcome in PAH - Time for a Change! Jean-Luc Vachiery, MD, Erasme University Hospital, Brussels, Belgium
7:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PHARM
Secondary Audiences: HF/HTX, LF/LTX, NHSAH

Session Summary: The purpose of this symposium is to review substances of abuse pre- and post-transplant. The symposium will focus on use of medications for pain and anxiety, smoking (nicotine and marijuana), and alcohol use. Speakers will present available evidence describing why these substances are harmful when used before and after transplant and offer guidance for cessation or therapeutic alternatives.

Chairs: Martin Zamora, MD and Vincent G. Valentine, MD
 

7:00 AM	‘Hurts So Good’: Analgesia Beyond Opioids Amanda Ingemi, PharmD, Sentara Norfolk General Hospital, Norfolk, VA, USA
7:15 AM	Q&A
7:20 AM	So, Light 'em if You've Got 'em - or Don't! Smoking Pre- and Post-Transplant Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands
7:35 AM	Q&A
7:40 AM	How Much is Too Much? Alcohol Use and Cessation Pre- and Post-Transplant Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
7:55 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: ID

Chairs: JoAnn Lindenfeld, MD and Sandet Singh Avatar Singh, MRCS, MSc
 

8:00 AM	(93) Early Utilization Trends and Outcomes of Hepatitis C Donor Hearts in the Era of Nucleic Acid Amplification Testing (NAT) and Direct Acting Antivirals (DAAs) S. Madan, S. R. Patel, O. Saeed, S. Forest, J. J. Shin, D. B. Sims, D. J. Goldstein, U. P. Jorde. Montefiore Medical Center, Bronx, NY
8:15 AM	(94) Use of Donor HCV NAT Positive Hearts: Expanding the Donor Pool? E. C. DePasquale1, C. J. Lum1, R. Chand1, W. Ragalie1, A. Chang1, A. Salimbangon1, M. Deng1, M. Cadeiras2, T. Khuu1, D. Vucicevic3, K. Pandya4, A. Ardehali1. 1UCLA, Los Angeles, CA, 2UC Davis, Sacramento, CA, 3Newark Beth Israel, Newark, NJ, 4USC, Los Angeles, CA
8:30 AM	(95) Clinical Experience with Heart Transplantation from Hepatitis C Positive Donors A. Reyentovich1, C. Gidea1, D. Smith2, B. Lonze3, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami4. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2CardioThoracic Surgery, NYU Langone Medical Center, New York, NY, 3Transplant Surgery, NYU Langone Medical Center, New York, NY, 4Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
8:45 AM	(96) Successful Transplantation of 58 Hepatitis C-Exposed Donor Hearts in the Era of Direct-Acting Antiviral Therapies K. Schlendorf, S. Zalawadiya, A. Shah, M. Wigger, R. Perri, M. Danter, M. Brinkley, J. Menachem, S. Brown Sacks, H. Ooi, L. Punnoose, K. Balsara, L. Stevenson, J. Awad, R. Fowler, H. O'dell, S. Ruzevich-Scholl, J. Lindenfeld. Vanderbilt University Medical Center, Nashville, TN
9:00 AM	(97) Regional Variation in Utilization of Hepatitis C-Positive Organs for Heart Transplantation in the United States E. M. DeFilippis1, A. R. Garan1, R. C. Givens1, L. K. Truby2, F. Latif1, S. W. Restaino1, K. Takeda1, H. Takayama1, Y. Naka1, P. C. Colombo1, M. A. Farr1, V. K. Topkara1. 1Columbia University Medical Center, New York, NY, 2Duke University Medical Center, Durham, NC
9:15 AM	(98) Trends in Renal Function among Heart-Transplant Recipients of Donor-Derived Hepatitis C Virus S. Zalawadiya1, J. Lindenfeld1, A. Shah2, M. Wigger1, M. Danter2, D. Brinkley1, J. Menachem1, L. Punnoose1, S. Brown Sacks1, H. Ooi1, K. Balsara2, R. Perri3, J. Awad3, S. Smith1, R. Fowler1, H. O'Dell3, C. Darragh3, S. Ruzevich-Scholl1, K. Schlendorf1. 1Heart Failure and Transplantation, Vanderbilt University Medical Center, Nashville, TN, 2Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 3Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN
9:30 AM	(99) Acceptance of HCV-Positive Donor Hearts Improves Organ Acceptance Selectivity: Single Center Experience K. J. Gaj1, D. A. D'Alessandro2, E. D. Bethea3, J. L. Gustafson3, M. A. Villavicencio-Theoduloz2, R. T. Chung3, G. D. Lewis4. 1Cardiac Transplantation, Massachusetts General Hospital, Boston, MA, 2Cardiothoracic Surgery, Massachusetts General Hospital, Boston, MA, 3Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA, 4Advanced Heart Disease, Massachusetts General Hospital, Boston, MA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: BSTR, PATH

Chairs: Pradeep P.A. Mammen, MD, FACC, FAHA and Markus Johannes Barten, MD, PhD
 

8:00 AM	(100) Increase in Donor Fraction Cell-Free DNA Correlates with Cellular and Antibody Mediated Rejection (ACR/AMR) in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study M. E. Richmond1, S. J. Kindel2, J. N. Schroder3, S. R. Deshpande4, D. P. Bichell5, M. A. Wigger6, K. R. Knecht7, E. Pahl8, N. A. Gaglianello9, P. M. Simpson10, W. T. Mahle11, A. T. Mitchell12, S. D. Zangwill13, M. E. Mitchell14. 1Pediatrics, Columbia University, New York, NY, 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, 3Surgery, Duke University, Durham, NC, 4Children's National, Washington, DC, 5Surgery, Vanderbilt University, Nashville, TN, 6Medicine, Vanderbilt University, Nashville, TN, 7Pediatrics, Arkansas Children's Hospital, Little Rock, AR, 8Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 9Medicine, Medical College of Wisconsin, Milwaukee, WI, 10Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 11Emory University, Atlanta, GA, 12Surgery and Biomedical Engineering, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, 13Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, 14Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI
8:15 AM	(101) Increase in Total Cell-Free DNA Correlates with Death in Adult and Pediatric Heart Transplant Recipients: DNA Based Transplant Rejection Test (DTRT)-A Prospective Blinded Multicenter NIH/NHLBI Funded Clinical Study S. D. Zangwill1, S. J. Kindel2, J. N. Schroder3, D. P. Bichell4, S. R. Deshpande5, M. A. Wigger6, M. E. Richmond7, K. R. Knecht8, N. A. Gaglianello9, E. Pahl10, P. M. Simpson11, W. T. Mahle12, A. T. Mitchell13, M. E. Mitchell14. 1Pediatrics, Phoenix Children's Hospital, Phoenix, AZ, 2Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI, 3Surgery, Duke University, Durham, NC, 4Surgery, Vanderbilt University, Nashville, TN, 5National Children's Hospital, Washington, DC, 6Medicine, Vanderbilt University, Nashville, TN, 7Pediatrics, Columbia University, New York, NY, 8Pediatrics, Arkansas Children's Hospital, Little Rock, AR, 9Medicine, Medical College of Wisconsin, Milwaukee, WI, 10Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 11Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 12Pediatrics, Emory University, Atlanta, GA, 13Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, 14Surgery, Pediatric Cardiothoracic Surgery, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI
8:30 AM	(102) Correlation of Human Myocardial Apoptosis with Pathology Rejection Grade and Levels of Donor-Derived Cell-Free DNA in Heart Transplantation S. Pattar1, F. Iqbal2, D. Isaac3, N. Fine3, S. C. Greenway4. 1Biochemistry & Molecular Biology, University of Calgary, Calgary, AB, Canada, 2Health Sciences, University of Calgary, Calgary, AB, Canada, 3Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Pediatrics, Cardiac Sciences, Biochem.& Molecular Bio/Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
8:45 AM	(103) Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes A. Loupy1, R. N. Woodward2, M. Machrus2, S. P. Pinney3, J. A. Kobashigawa4. 1Hospital Necker, Paris, France, 2CareDx, Brisbane, CA, 3Mt Sinai Health System, New York, NY, 4Cedars-Sinai Heart Institute, Los Angeles, CA
9:00 AM	(104) Molecular Microscope Determinants of Graft Survival in the INTERHEART Study J. Reeve1, D. H. Kim1, M. G. Crespo-Leiro2, J. Kobashigawa3, L. Potena4, M. Deng5, M. Cadeiras5, E. C. Depasquale5, A. Loupy6, P. Macdonald7, A. Zuckermann8, A. Z. Aliabadi8, J. Goekler8, M. Parkes1, P. F. Halloran1. 1University of Alberta, Edmonton, AB, Canada, 2Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of Bologna, Bologna, Italy, 5Ronald Reagan UCLA Medical Center, Los Angeles, CA, 6Hôpital Necker, Paris, France, 7The Victor Chang Cardiac Research Institute, Sydney, Australia, 8Medical University of Vienna, Vienna, Austria
9:15 AM	(105) miR-208a-5p and miR-135a-5p in Formalin Fixed Paraffin Embedded Endo-Myocardial Monitoring Biopsies Discriminate Rejection from Cardiac Infection A. Di Francesco1, M. Fedrigo1, C. Castellani1, D. Gregori1, D. Santovito2, L. Natarelli2, G. Toscano1, T. Bottio1, G. Thiene1, M. Valente1, M. Valente1, A. Schober2, C. Basso1, G. Gerosa1, A. Angelini1. 1Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy, 2Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximillians University (LMU), Munich, Germany
9:30 AM	(106) Circulating, Cell-Free, MicroRNA Sequencing to Diagnose Cardiac Allograft Rejection and Distinguish Rejection Subtype P. Shah1, S. Agbor-Enoh2, W. Zhu3, M. Harpole3, Y. Wakabayashi4, K. Bhatti2, P. Kothiyal3, U. Fideli2, S. Hsu5, M. E. Rodrigo6, E. Feller7, K. B. Shah8, R. K. Iyer3, J. Zhu4, H. Valantine2. 1Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2National Heart, Lung and Blood Institute, Bethesda, MD, 3Inova Translational Medicine Institute, Falls Church, VA, 4Mokobio, Rockville, MD, 5Heart Failure and Transplantation, Johns Hopkins University, Baltimore, MD, 6Heart Failure and Transplantation, Washington Hospital Center, DC, DC, 7Heart Failure and Transplantation, University of Maryland, Baltimore, MD, 8Heart Failure and Transplantation, Virginia Commonwealth University, Richmond, VA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audiences: LF/LTX, PATH

Session Summary: This symposium will review the evidence and discuss the utility of detection of pathogens from surveillance bronchoscopies after lung transplantation. Evidence will be presented regarding the interpretation and treatment of positive culture results from surveillance bronchoscopy. We will review and analyze the management/treatment of bacteria, fungi, atypical mycobacteria and CMV in asymptomatic patients.

Chairs: Are Holm, MD and Stephanie M. Pouch, MD
 

8:00 AM	‘Critter Country’: Treatment and Eradication of Bacteria and Bacterial Biome Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland
8:15 AM	Q&A
8:20 AM	‘Fungal Frontierland’: Pathogens or Colonizers? Me-Linh Luong, MD, St. Luc Hospital, Montréal, QC, Canada
8:35 AM	Q&A
8:40 AM	‘Off Main Street’: Atypical Mycobacteria - What, When and How to Manage Fernanda Silveira, MD, University of Pittsburgh, Pittsburgh, PA, USA
8:55 AM	Q&A
9:00 AM	‘CMV Square’: Lung Transplant Recipients with CMV Positivity in a Bronchoscopy without CMV DNAemia Jutta K. Preiksaitis, MD, University of Alberta, Edmonton, AB, Canada
9:15 AM	Q&A
9:20 AM	‘Tomorrowland’: A Case-Based Approach to Managing Bronchoscopy Results Shalika B. Katugaha, MD, Inova Fairfax Hospital, Annandale, VA, USA
9:40 AM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX

Chairs: Alexis Slama, MD and Daniel F. Dilling, MD
 

8:00 AM	(107) Validation of an EVLP Perfusate Diagnostic Test for the Prediction of Lung Transplant Outcomes A. T. Sage1, M. Richard-Greenblatt2, K. J. Zhong2, M. B. Snow1, M. Babits1, M. Chen1, H. Gokhale1, M. Galasso1, H. Shan1, M. Cypel1, M. Liu1, K. C. Kain2, S. Keshavjee1. 1Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada
8:15 AM	(108) A Clinical Trial Evaluating the Effects of Ultra-Violet C treatment (UVC) during Ex Vivo Lung Perfusion (EVLP) as a Method of Inactivating Hepatitis C Infection in Donor Lungs M. Cypel1, M. Galasso1, R. Ribeiro1, B. Wilson1, V. Bagnato2, C. Kurachi2, M. Chen1, D. Kumar1, T. K. Waddell1, L. G. Singer1, S. Keshavjee1, A. Humar1, J. Feld1. 1Toronto General Hospital, Toronto, ON, Canada, 2Sao Paulo University, Sao Carlos, Brazil
8:30 AM	(109) Stratification Risk Analysis in Bridging Patients to Lung Transplant on ECMO: The STABLE Recipient Risk Score A. Habertheuer, T. Richards, F. Sertic, M. Crespo, M. Molina, P. Vallabhajosyula, E. Cantu, Y. Suzuki, D. Diagne, C. Bermudez. Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
8:45 AM	(110) Ex-Vivo Lung Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus T. J. Ku1, M. Cypel2, R. V. Ribeiro2, V. H. Ferreira1, D. Kumar1, A. Humar1. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada
9:00 AM	(111) Early Outcomes with the Use of ExtraCorporeal Membrane Oxygenation as a Bridge to Combined Heart and Lung Transplant F. Sertic, M. M. Crespo, A. Habertheuer, D. Diagne, L. Chavez, T. Richards, M. Molina, Y. Suzuki, E. Rame, J. Wald, E. Cantu, C. Bermudez. University of Pennsylvania, Philadelphia, PA
9:15 AM	(112) Increasing Use of EVLP in the United States: Data from the OPTN/UNOS R. R. Lehman1, K. Uccellini1, E. Lease2, R. Daly3, K. M. Chan4. 1United Network for Organ Sharing, Richmond, VA, 2University of Washington, Seattle, WA, 3Mayo Clinic, Rochester, MN, 4University of Michigan, Ann Arbor, MI
9:30 AM	(113) Central Ambulatory Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation P. Downey1, W. Ragalie1, D. Ross2, A. Ardehali1. 1Cardiothoracic Surgery, UCLA, Los Angeles, CA, 2Pulmonary and Critical Care Medicine, UCLA, Los Angeles, CA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: MCS

Session Summary: This symposium will examine state of the art knowledge on device programming and medical management of LVAD patients. Current controversies such as the utility of platelet function monitoring and invasive hemodynamic testing will be reviewed and debated.

Chairs: Marco Masetti, MD, PhD, and Garrick C. Stewart, MD
 

8:00 AM	What are We Treating with Heart Failure Therapy after MCS: the LV, the RV, the Periphery or Ourselves? Gabriella Masciocco, MD, A.O. Niguarda Ca ' Granda, Milan, Italy
8:20 AM	Antiplatelet Therapy: Fixed Dose or Functional Assays? Jeffrey J. Teuteberg, MD, Stanford University School of Medicine, Stanford, CA, USA
8:35 AM	Time in Therapeutic Range: Is There an Optimal Way to Manage INR? Douglas L. Jennings, PharmD, New York-Presbyterian Hospital, New York, NY, USA
8:50 AM	Pump Data: Do We Need It to Decide Changes in Therapy? Thomas Schlöglhofer, MSc, Medical University of Vienna, Vienna, Austria
9:05 AM	DEBATE: You Need Information from Invasive Hemodynamics to Properly Manage an LVAD (PRO) Nir Uriel, MD, University of Chicago, Chicago, IL, USA
9:20 AM	DEBATE: You Need Information from Invasive Hemodynamics to Properly Manage an LVAD (CON) Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA
9:35 PM	10-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: PATH
Secondary Audiences: BSTR, HTX, LTX, PEDS

Chairs: Patrick Bruneval, MD and Brandon T. Larsen, MD, PhD
 

8:00 AM	(114) Gene Expression in Formalin-Fixed Paraffin-Embedded Lung Transplant Biopsies: Correlation between Molecular and Histologic Phenotypes B. Adam, K. Du, S. Rotich, M. Mengel. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
8:15 AM	(115) Occurrence and Risk Factors for Acute Lung Injury (ALI) and Organizing Pneumonia (OP) after Lung Transplant E. N. Pavlisko1, M. L. Neely1, H. Kopetskie2, D. Hwang3, C. F. Farver4, A. V. Arrossi4, W. D. Wallace5, P. Illei6, M. Sever7, J. Kirchner1, C. W. Frankel1, L. D. Snyder1, T. Martinu8, M. Y. Shino9, N. Williams10, M. A. Robien11, L. G. Singer8, M. Budev4, W. Tsuang4, P. D. Shah6, J. M. Reynolds1, S. Weigt9, J. A. Belperio9, S. M. Palmer1, J. L. Todd1. 1Duke University Medical Center, Durham, NC, 2Rho Federal Systems Division, Chapel Hill, NC, 3Sunnybrook Health Sciences Center, Toronto, ON, Canada, 4Cleveland Clinic, Cleveland, OH, 5University of California, Los Angeles, CA, 6Johns Hopkins University, Baltimore, MD, 7Rho Federal Systems Division, Chapal Hill, NC, 8University of Toronto, Toronto, ON, Canada, 9University of California Los Angeles, Los Angeles, CA, 10National Institute of Allergy and Infectious Disease, Bathesda, MD, 11National Institute of Allergy and Infectious Disease, Bethesda, MD
8:30 AM	(116) The Prognostic Value of Fibrin and Organizing Pneumonia in Transbronchial Biopsies from Lung Transplant Patients A. Vanstapel1, S. E. Verleden1, A. Van Herck1, J. Kaes1, T. Heigl1, A. Sacreas1, E. Verbeken2, B. Weynand2, B. M. Vanaudenaerde1, G. M. Verleden1, R. Vos1. 1Leuven Lung Transplant Unit, KU Leuven - UH Leuven, Leuven, Belgium, 2Department of Imaging and Pathology, KU Leuven - UH Leuven, Leuven, Belgium
8:45 AM	(117) Sarcoidosis Associated Pulmonary Hypertension: Correlation of Vascular Morphologic Changes with Hemodynamic Data in Explanted Lungs P. Chung, K. Warrior, M. Reid, R. Nigdelioglu, S. Boyes, V. Ananthanarayanan, S. Quddus. Pulmonary and Critical Care, Loyola University Medical Center, Maywood, IL
9:00 AM	(118) What are the Histopathologic Findings in Pulmonary Allografts with Graft Failure? R. E. White, A. P. Burke. Pathology, University of Maryland, Baltimore, MD
9:15 AM	(119) Endomyocardial Biopsy Findings in Pediatric Heart Transplants Recipients with Positive HLA Associated Antibodies: Review of a Cohort with Poor Outcomes A. Shenoy1, A. K. Esnakula2, S. S. Goldstein2, B. A. Pietra3, M. S. Bleiweis3, F. J. Fricker3, D. Gupta3. 1Departments of Pathology, Immunology and Laboratory Medicine & Pediatrics, University of Florida, Gainesville, FL, 2Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 3Congenital Heart Center, University of Florida, Gainesville, FL
9:30 AM	(120) Accelerated Cardiac Allograft Vasculopathy: A Clinical and Pathologic Correlation Study D. V. Miller1, M. Revelo1, E. Hammond1, B. Kfoury2, K. Afshar2, K. Molina3, R. Alharethi2. 1Pathology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 2Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT, 3Pediatric Cardiology, UTAH Cardiac Transplant Program, Salt Lake City, UT

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: PEDS
Secondary Audiences: LTX

Chairs: Ernestina Melicoff-Portillo, MD and Brigitte W. Willemse, MD, PhD
 

8:00 AM	(121) Pediatric Patients with Pulmonary Vascular and Restrictive Lung Disease Suffer Disproportionately High Waitlist Mortality K. W. Riggs1, D. B. Colohan1, R. Rizwan1, C. Towe2, M. Schecter2, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
8:15 AM	(122) Outcomes of Cystic Fibrosis and Non-Cystic Fibrosis Pediatric Lung Transplants: An ISHLT Registry Study J. S. Nelson1, T. M. Maul1, C. G. Hurtado2, P. D. Wearden1. 1Cardiovascular Services, Nemours Children's Hospital, Orlando, FL, 2University of Central Florida College of Medicine, Orlando, FL
8:30 AM	(123) Pediatric Lung Transplantation: Fit for Split? T. Martens1, M. Kanakis2, H. Spencer3, N. Muthialu4. 1Cardiothoracic Surgery, University Hospital, Ghent, Belgium, 2Cardiothoracic Surgery, Onassis Cardiothoracic Surgery Centre, Athens, Greece, 3Transplantation, Great Ormond Street Hospital, London, United Kingdom, 4Cardiothoracic Surgery, Great Ormond Street Hospital, London, United Kingdom
8:45 AM	(124) Etiology of Failure Predicts Heart-Lung Transplant Candidate's Waitlist Survival K. W. Riggs1, J. L. Chapman1, M. Schecter2, C. Towe2, R. Bryant1, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
9:00 AM	(125) Is the Current Era Better for Pediatric Heart-Lung Transplantation? K. W. Riggs1, J. L. Chapman1, M. Schecter2, C. Towe2, R. Bryant1, F. Zafar1, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH
9:15 AM	(126) Proinflammatory Cytokines as Biomarkers for BOS, Death, or Retransplantation after Lung Transplantation C. K. Conrad. Pediatrics, Lucile Packard Children's Hospital, Palo Alto, CA
9:30 AM	(127) Five-Year Experience with Treatment of Early Donor Specific Anti-HLA Antibodies in Pediatric Lung Transplant Recipients F. Ius1, N. Schwerk2, C. Müller2, W. Sommer1, M. Verboom3, M. Hallensleben3, J. Salman1, T. Siemeni1, C. Kühn1, M. Avsar1, D. Bobylev1, J. Carlens2, L. Bayir2, G. Hansen2, R. Blasczyk3, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Paediatric Pulmonology, Allergology, and Neonatology, Hannover Medical School, Hannover, Germany, 3Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audiences: NHSAH

Chairs: George G. Sokos, DO and Wandy Chan, PhD, FRACP
 

10:15 AM	(128) Genomic Prediction of One Year Survival Status Related to Functional Recovery Potential in Advanced Heart Failure Patients Undergoing Mechanical Circulatory Support G. Bondar1, T. Bao1, M. Kurani1, D. L. Bhaskar1, A. Le1, R. Dod1, Y. Khachatoorian1, A. Aliyari1, E. Higuchi1, E. Oh1, K. Patel1, M. Cadeiras2, J. Schaenman1, L. Masukawa1, S. Kupiec-Weglinski3, V. Groysberg1, M. Bakir1, E. Depasquale1, M. Kamath1, D. Liem1, J. Meltzer1, M. Kwon1, M. Rossetti1, D. Elashoff1, X. Li1, E. Reed1, P. Ping1, M. C. Deng1. 1David-Geffen Sch Med, Los Angeles, CA, 2University of California Davis School of Medicine, Sacramento, CA, 3Cornell University, Ithaca, NY
10:30 AM	(129) Impact of Frailty on Health-Related Quality of Life from before to 6 Months after Surgery: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study K. Ghafourian1, A. C. Andrei2, Y. Xu2, C. W. Yancy1, H. Adam2, D. T. Pham2, K. L. Grady2. 1Cardiology, Northwestern University, Chicago, IL, 2Surgery, Northwestern University, Chicago, IL
10:45 AM	(130) Leg Muscle Strength Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure J. Youn1, E. Yoon1, H. Choi2, I. Kim3, J. Lee1, S. Lee1, S. Han1, S. Kang4. 1Dongtan Sacred Heart Hospital, Hallym University, Hwaseong, Korea, Republic of, 2Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of, 3Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of, 4Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
11:00 AM	(131) Comparison of Percutaneous Ventricular Assist Device and Intra-Aortic Balloon Pump for Cardiogenic Shock A. Y. Lee1, C. Y. Guerrero-Miranda1, T. Nisar2, A. K. Jamil2, A. Perez1, D. Tangellamundi1, J. Felius2, S. A. Hall1, D. Wencker1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX
11:15 AM	(132) Characteristics and Outcomes of Patients with Cardiogenic Shock Complicated by Acute Kidney Injury Requiring Hemodialysis C. Inampudi1, O. Adegbala2, E. Akintoye1, P. Alvarez1, A. Briasoulis1. 1Internal Medicine - Cardiology, Univ of Iowa Hospital, Iowa City, IA, 2Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey, NJ
11:30 AM	(133) LVAD Survival May Be Predicted by Preoperative Lymphopenia K. Stawiarski1, O. Agboola2, D. Jacoby3, L. Bellumkonda3, L. Sugeng3, T. Ahmad3, M. Chen3, G. McCloskey2, A. Geirsson2, M. Anwar2, P. Bonde2. 1Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, 2Yale School of Medicine, New Haven, CT, 3Yale School of Medicine, Bridgeport, CT
11:45 AM	(134) Differences in Health-Related Quality of Life by Socio-Demographic Characteristics: Findings from the Sustaining Quality of Life of the Aged: Transplant or Mechanical Support (SUSTAIN-IT) Study L. Uppalapati1, A. Andrei2, C. Yancy3, Y. Xu2, H. Adam2, D. Pham2, K. L. Grady2. 1Northwestern University, Chicago, IL, 2Surgery / Cardiac Surgery, Northwestern University, Chicago, IL, 3Medicine, Northwestern University, Chicago, IL

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ID
Secondary Audiences: HTX, LTX, PEDS

Chairs: Valentina Stosor, MD and Saima Aslam, MD, MS
 

10:15 AM	(135) Routine Utilization of NAT Negative PHS Increased Risk Thoracic Organs Appears Safe and Effective in Increasing Organ Supply for Transplantation K. J. Gaj1, L. Irwin1, A. Leifer1, M. A. Villavicencio-Theoduloz2, K. Turvey1, G. D. Lewis3, C. Kotton4, D. A. D'Alessandro1. 1Transplant Surgery, Massachusetts General Hospital, Boston, MA, 2Transplant Surgery, Massachusetts General Hospital, Bosotn, MA, 3Advanced Heart Disease, Massachusetts General Hospital, Boston, MA, 4Infectious Disease Division, Massachusetts General Hospital, Boston, MA
10:30 AM	(136) Transplantation of NAT+HCV Donor Lungs into Non-Infected Recipients Followed by Treatment with Sofosbuvir/Velpatasvir (S/V) M. Cypel, J. Feld, L. G. Singer, N. Marks, I. Bahinskaya, M. Kuczynski, D. Kumar, M. Galasso, R. Ribeiro, J. Yeung, L. Donahoe, A. Pierre, M. de Perrot, K. Yasufuku, T. K. Waddell, S. Keshavjee, A. Humar, A. Humar. Toronto General Hospital, Toronto, ON, Canada
10:45 AM	(137) Preemptive Pan-Genotypic Direct Acting Antiviral Therapy in Donor HCV-Positive to Recipient HCV-Negative Cardiac Transplantation Produces Viral Clearance and is Associated with Favorable Outcomes G. D. Lewis, E. D. Bethea, K. Gaj, J. Gustafson, A. Dugal, K. Turvey, E. Coglianese, S. S. Thomas, C. Newton-Cheh, N. E. Ibrahim, W. D. Carlson, R. V. Shah, R. V. Shah, J. E. Ho, M. Nayor, J. K. Steiner, M. E. Afari, T. Lebeis, J. C. Madsen, M. A. Villavicencio-Theoduloz, R. T. Chung, D. A. D'Alessandro. Massachusetts General Hospital, Boston, MA
11:00 AM	(138) Magnitude of Recipient Viremia after Heart Transplantation from HCV Viremic Donors and Time to Clearance with Therapy C. G. Gidea1, A. Reyentovich1, D. Smith2, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami2. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
11:15 AM	(139) The Impact of Utilizing Hepatitis C Virus Nucleic Acid Test-Positive Donor Heart on Heart Transplant Waitlist Time Y. K. Gernhofer1, M. Brambatti2, B. H. Greenberg2, E. Adler2, S. Aslam3, V. Pretorius1. 1Cardiothoracic Surgery, UC San Diego, San Diego, CA, 2Cardiology, UC San Diego, San Diego, CA, 3Infectious Diseases, UC San Diego, San Diego, CA
11:30 AM	(140) The Impact of HCV Viremia in Heart Transplant Recipients from Donors with HCV Infection on Acute and Humoral Cellular Rejection C. G. Gidea1, N. Narula2, A. Reyentovich1, D. Smith3, J. Pavone1, S. Katz1, S. Pan1, S. Rao1, T. Saraon1, N. Moazami3. 1Heart Transplant, NYU Langone Medical Center, New York, NY, 2Pathology, NYU Langone Medical Center, New York, NY, 3Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY
11:45 AM	(141) Outcomes of Heart and Heart-Kidney Transplantation from Hepatitis C Virus (HCV) Positive Donors into HCV Negative Recipients S. Aslam1, I. Yumul2, M. Mariski1, V. Pretorius1, E. Adler1. 1University of California, San Diego, San Diego, CA, 2University of Iowa, Iowa City, IA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: LF/LTX
Secondary Audience: MCS

Session Summary: This symposium will bring experts in Ex-Vivo Lung Perfusion and donor lung management from all over the world. Current practices, different models, ongoing clinical trials with EVLP and added therapeutics will be discussed. The attendee will increase his or her understanding of the technique, its applications and future directions.

Chairs: John Dark, MB, FRCS and Tiago Machuca, MD, PhD
 

10:15 AM	Implementation of High Volume Clinical EVLP: The Toronto Model Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, ON, Canada
10:30 AM	Rationale for Portable EVLP Wiebke Sommer, MD, Hannover Medical School, Hannover, Germany
10:45 AM	Benefits and Barriers of a Do-It-Yourself EVLP Program Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia
11:00 AM	Organ Procurement Organization-based EVLP Program Duane Davis, MD, MBA, Florida Hospital, Orlando, FL, USA
11:15 AM	Experience with a Third-Party EVLP Program Kenneth R. McCurry, MD, FACS, Cleveland Clinic, Cleveland, OH, USA
11:30 AM	The Role of Biomarkers in EVLP Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, UK
11:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS

Chairs: Sai Bhagra, MBBS and Erin Coglanese, MD
 

10:15 AM	(142) Understanding Risk Factors for Stroke Subtypes in the ENDURANCE Trials S. Cho1, R. Starling2, J. Teuteberg3, J. Rogers4, F. Pagani5, P. Shah6, K. Uchino7, T. Vassiliades8. 1John Hopkins University, Baltimore, MD, 2Cardiology, Cleveland Clinic, Cleveland, OH, 3Cardiology, Stanford University, Stanford, CA, 4Duke University, Durham, NC, 5University of Michigan, Ann Arbor, MI, 6Cardiology, Inova Fairfax, Falls Church, VA, 7Cleveland Clinic, Cleveland, OH, 8Medtronic, Framingham
10:30 AM	(143) Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort N. Uriel1, M. Mehra2. 1University of Chicago, Chicago, IL, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
10:45 AM	(144) Two-Year Outcomes in Real World Patients Treated with Heartmate 3TM Left Ventricular Assist Device for Advanced Heart Failure: Data from the ELEVATE Registry D. Saeed1, J. Garbade1, F. Gustafsson2, J. Lavee3, M. Morshuis4, D. Zimpfer5, E. Potapov6, Y. Pya7, J. Schmitto8, S. M. Shaw9. 1Department for Cardiac Surgery, Leipzig Heart Centre, Leipzig, Germany, 2The Heart Centre, Rigshospitalet, Copenhagen, Denmark, 3Heart Transplantation Unit, Leviev Heart Center, Tel Aviv, Israel, 4Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, 5Department of Surgery, Medical University of Vienna, Vienna, Austria, 6Deutsches Herzzentrum Berlin, Berlin, Germany, 7National Research Center for Cardiac Surgery, Astana, Kazakhstan, 8Medizinische Hochschule Hannover, Hannover, Germany, 9Heart and Lung Transplant Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom,
11:00 AM	(145) Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices P. Shah1, C. Mahr2, J. Rogers3, M. Kiernan4, S. Boyce5, N. A. Mokadam6, F. Pagani7, T. Vassiliades8, J. Teuteberg9. 1Cardiology, Inova Fairfax, Falls Church, VA, 2Cardiology, University of Washington, Seattle, WA, 3Cardiology, Duke University, Durham, NC, 4Cardiology, Tufts University, Boston, MA, 5Cardiac Surgery, Washington Hospital Center, Washington, DC, 6Cardiac Surgery, University of Washington, Seattle, WA, 7Cardiac Surgery, University of Michigan, Ann Arbor, MI, 8Medtronic, Framingham, MA, 9Cardiology, Stanford University, Stanford, CA
11:15 AM	(146) Apixaban in HVAD Patients Non-Compliant to Standard Vitamin-K-Antagonism S. Schulte-Eistrup1, N. Mayer-Wingert1, N. Reiss2, J. Sindermann3, H. Warnecke1. 1Cardiac Surgery, Schuechtermann Klinik, Bad Rothenfelde, Germany, 2Clinical Research, Schuechtermann Klinik, Bad Rothenfelde, Germany, 3Rehabilitation, Schuechtermann Klinik, Bad Rothenfelde, Germany
11:30 AM	(147) Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or Death J. A. Fried1, H. Lumish1, A. M. Zuver1, A. R. Garan1, V. K. Topkara1, B. Cagliostro1, G. Parkis2, M. Cevasco2, M. T. Pineda2, G. M. Mondellini1, K. Ross2, L. Witer2, H. Takayama2, K. Takeda2, Y. Naka2, M. Yuzefpolskaya1, R. T. Demmer3, P. C. Colombo1. 1Cardiology, Columbia University Medical Center, New York, NY, 2Department of Surgery, Columbia University Medical Center, New York, NY, 3Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
11:45 AM	(148) Occurrence and Clinical Patterns of Stroke Based on Arterial Cannulation Strategy during Veno-Arterial Extracorporeal Membrane Oxygenation Support M. Nishikawa, J. Willey, A. R. Garan, M. Cevasco, L. Witer, J. Sanchez, P. Kurlansky, A. Kirtane, D. Brodie, M. Yuzefpolskaya, P. Colombo, H. Takayama, Y. Naka, K. Takeda. Columbia University Irving Medical Center, New York, NY

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS

Chairs: William Hiesinger, MD and J. Eduardo Rame, MD
 

10:15 AM	(149) Course and Clinical Impact of Tricuspid Regurgitation after LVAD Implantation: An Analysis of the EUROMACS Registry K. Veen1, M. M. Mokhles1, O. I. Soliman1, T. M. de By2, P. Mohacsi3, F. Schoenrath4, L. Paluszkiewicz5, A. J. Bogers1, J. J. Takkenberg1, K. Caliskan1. 1Erasmus MC, Rotterdam, Netherlands, 2EUROMACS Registry, Windsor, United Kingdom, 3University Hospital Zurich, Zurich, Switzerland, 4German Heart Centre Berlin, Berlin, Germany, 5Heart and Diabetes Centre NRW, Bad Oeynhausen, Germany
10:30 AM	(150) Aortic Insufficiency is Associated with Hemocompatibility-Related Adverse Events in LVAD Patients T. Imamura, J. Raikhelkar, G. Kim, B. Smith, S. Kalantari, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, J. Grinstein, D. Nitta, T. Fujino, C. Juricek, D. Rodgers, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
10:45 AM	(151) Impact of Pre-Op Mitral Regurgitation Following Left Ventricular Assist Device Implant G. N. Coyan1, B. Pierce2, Z. Rhinehart2, F. Thoma3, W. Katz2, A. Kilic1, R. Kormos1, C. M. Sciortino1. 1Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, 2Cardiology, University of Pittsburgh, Pittsburgh, PA, 3Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA,
11:00 AM	(152) Longitudinal Trend of Tricuspid Regurgitation Following Left Ventricular Assist Device Implantation T. Fujino, T. Imamura, D. Nitta, D. Rodgers, A. Nguyen, B. Chung, J. Raikhelkar, B. Smith, I. Ebong, N. Narang, L. Holzhauser, T. Ota, V. Jeevanandam, G. Kim, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
11:15 AM	(153) TAVI in LVAD Patients with Aortic Insufficiency M. N. Belkin, T. Imamura, A. J. Kanelidis, L. Holzhauser, I. Ebong, N. Narang, J. E. Blair, S. Nathan, J. D. Paul, A. P. Shah, B. Chung, A. Nguyen, B. Smith, S. Kalantari, J. Raikhelkar, N. Sarswat, G. Kim, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
11:30 AM	(154) Increased Incidence of De Novo Aortic Incompetence in Patients Supported with Impella Prior to LVAD Implantation S. D. Rao, B. Johnson, V. Medina, E. Rame, L. Goldberg, J. Wald, P. Atluri, C. Bermudez, M. Acker, E. Y. Birati. University of Pennsylvania, Philadelphia, PA
11:45 AM	(155) Impact of Concomitant Valvular Surgery on Patients Undergoing LVAD Implantation K. Y. Mulumba1, P. Kasinpila1, R. Fong1, S. Kong1, L. Hecker1, R. Nissan1, D. Banerjee2, J. Teuteberg2, Y. Shudo1, Y. Woo1, W. Hiesinger1. 1Cardiothoracic Surgery, Stanford University, Palo Alto, CA, 2Cardiology, Stanford University, Palo Alto, CA

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PATH
Secondary Audiences: HF/HTX, LF/LTX

Session Summary: The postmortem examination ("autopsy") is underutilized in modern medicine, but provides critical information to the clinicians, families and loved ones of the decedent to help them understand the decedent's clinical course. Data obtained from autopsies may be used by hospital quality personnel, researchers, policy makers, registries and device manufacturers to improve the state of thoracic transplantation and mechanical circulatory support therapy.

Chairs: Lorriana E. Leard, MD and Carmela Tan, MD
 

10:15 AM	The Autopsy in the Modern Era: What the Clinician Still Would Like to Gain from an Autopsy Stephen C. Clark, MD, Freeman Hospital, Newcastle Upon Tyne, UK
10:30 AM	What the Pathologist Can Tell: More Than Just Cause of Death Anja C. Roden, MD, Mayo Clinic, Rochester, MN, USA
10:45 AM	How is a Postmortem Examination Performed: Frequently Asked Questions Billie S. Fyfe-Kirschner, MD, Robert Wood Johnson School of Medicine, New Brunswick, NJ, USA
11:00 AM	The Autopsy in the Mechanical Circulatory Support Patient Robert F. Padera, MD, PhD, Brigham & Women's Hospital, Boston, MA, USA
11:15 AM	The Autopsy in the Thoracic Transplant Patient Ornella Leone, MD, S. Orsola Hospital, Bologna, Italy
11:30 AM	The ‘Rapid Autopsy’: A Tool for Scientific Inquiry Dylan V. Miller, MD, Intermountain Central Lab, Murray, UT, USA
11:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PEDS
Secondary Audiences: HTX, MCS

Session Summary: Pediatric and congenital heart disease VAD support is a challenge because the population is heterogenous, VADs were not designed for complex anatomy and physiology, and compared with adults, the numbers, data and collective experience are extremely limited. Despite these challenges, pediatric centers have successfully adapted and utilized VADs to improve outcomes. This symposium will provide an opportunity for the pediatric community to share their experience with the broader MCS community.

Chairs: Angela Lorts, MD and Ulrich Jorde, MD
 

10:15 AM	Not Just Small Adults: Outcomes of Pediatric Patients with Continuous Flow Devices Christina J. VanderPluym, MD, Boston Children's Hospital, Boston, MA, USA
10:30 AM	Not Just Small Adults: Novel Antithrombosis Strategies Used in Pediatric VADs Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
10:45 AM	Not-So-Temporary Circulatory Support Aamir Jeewa, MD, Hospital for Sick Children, Toronto, ON, Canada
11:00 AM	Optimizing Hemodynamics of Continuous Flow VADS for Small Patients Lucas Eastaugh, MBBS, Royal Children's Hospital, Melbourne, Australia
11:15 AM	One Size Fits All? Strategies for Using Implantable VADs in Small Patients Antonio Amodeo, MD, Bambino Gesu Pediatric Hospital, Rome, Italy
11:30 AM	Building Bridges: Collaborative Learning to Improve Outcomes in VAD Care David M. Peng, MD, University of Michigan, Ann Arbor, MI, USA
11:45 AM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audiences: ID, LF/LTX, MCS, PEDS, PH

Session Summary: This symposium will highlight the most exciting publications in JHLT over the past year, each paper followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

Chairs: Manreet Kanwar, MD and Martin Schweiger, PhD, MD
 

1:45 PM	JHLT Best Papers of 2018 Patricia A. Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA
1:50 PM	Highlights of Heart Transplantation and MCS Simon Pecha, MD, University Hospital Hamburg, Hamburg, Germany
2:05 PM	Invited Discussant in Heart Transplantation and MCS Francis D. Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA
2:15 PM	Highlights of Lung Transplantation and Pulmonary Hypertension Peter Riddell, MBBS, Mater Misericordiae University Hospital, Dublin, Ireland
2:30 PM	Invited Discussant in Lung Transplantation and Pulmonary Hypertension Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA, USA
2:40 PM	Highlights of Pediatric Heart and Lung Transplantation Ann R. Punnoose, MD, Children's Hospital of Wisconsin, Milwaukee, WI, USA
2:55 PM	Invited Discussant in Pediatric Heart and Lung Transplantation Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA
3:05 PM	Highlights of Infectious Disease Jonathan M. Hand, MD, Ochsner Medical Center, New Orleans, LA, USA
2:15 PM	Invited Discussant in Infectious Diseases Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: BSTR
Secondary Audience: HTX, LTX, PATH

Chairs: Andrew E. Gelman, PhD and Frank D'Ovidio, MD, PhD
 

1:45 PM	(156) Mitochondrial DNA Mismatches in Thoracic Transplantation: Potential Triggers of Allograft Immunogenicity A. Marishta1, Y. Yang1, X. Hu2, M. Jang1, K. Cuttin1, A. Jackson3, H. Luikart4, K. Bhatti1, U. Fideli1, T. Deuse2, K. Khush4, S. Schrepfer2, S. Agbor-Enoh1, H. Valantine1. 1Genomic Research Alliance for Transplantation (GRAfT), Laboratory of Transplantation Genomics, National Heart, Lung, and Blood Institute, Bethesda, MD, 2Department of Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco (UCSF), San Francisco, CA, 3Pulmonary and Critical Care Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, 4Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
2:05 PM	(157) Effects of Nissen Fundoplication on Markers of Microaspiration and Inflammation after Lung Transplantation K. C. Zhang1, S. E. Hunter1, E. Huszti2, M. Ahmed1, L. Levy1, K. M. Boonstra1, A. T. Sage1, S. Azad1, R. Zamel1, C. Frankel3, M. Budev4, P. Shah5, L. D. Snyder3, J. Belperio6, L. G. Singer1, S. S. Weigt6, J. L. Todd3, S. Keshavjee1, S. M. Palmer3, T. Martinu1, *. for the CTOT-20 Investigators1. 1Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 2Biostatistics Research Unit, University Health Network, Toronto, ON, Canada, 3Duke University Medical Center, Durham, NC, 4Cleveland Clinic, Cleveland, OH, 5Johns Hopkins University Hospital, Baltimore, MD, 6UCLA Medical Center, Los Angeles, CA
2:25 PM	(158) ABO Tolerance Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes J. Fersovich1, B. Motyka1, I. Adam1, J. Pearcey1, K. Tao1, C. W. Cairo2, P. J. Cowan3, L. J. West1. 1Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, 2Dept Chemistry, University of Alberta, Edmonton, AB, Canada, 3Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia
2:45 PM	(159) Modulating Mitochondrial Fusion/Fission Induces Immunoprotective Effects in Models of Cardiac Transplantation D. T. Tran1, Z. Tu2, C. Atkinson1, S. N. Nadig1. 1Microbiology & Immunology, Surgery, Medical University of South Carolina, Charleston, SC, 2Microbiology & Immunology, Medical University of South Carolina, Charleston, SC
3:05 PM	(160) The Evaluation of Coronary Artery Function during Normothermic Ex Situ Heart Perfusion X. Qi, S. Hatami, B. Tkachuk, M. Buchko, S. Bozso, D. He, S. Himmat, C. W. White, J. Nagendran, D. H. Freed. Surgery, University of Alberta, Edmonton, AB, Canada

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: ID, PHARM

Chairs: Darko Vucicevic, MD and Monica Colvin, MD
 

1:45 PM	(161) Late-Breaking Clinical Trial: 10-Year Follow-Up of the Everolimus versus Azathioprine Multi-National Study J. A. Kobashigawa1, R. Starling2, E. Passano1, P. Bernhardt3, B. Azarbal1, R. Cheng1, F. Esmailian1, K. Khush4, D. Mancini5, J. Patel1, T. Sato1, S. Varnous6. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cleveland Clinic, Cleveland, OH, 3Novartis Pharmaceuticals, Basel, Switzerland, 4Stanford University, Palo Alto, CA, 5Mount Sinai, New York, NY, 6APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France
2:00 PM	(162) Effect of Donor Simvastatin Treatment on Gene Expression Profiles in Human Cardiac Allografts during Ischemia-Reperfusion Injury R. Krebs1, M. Kankainen2, E. Holmström1, K. Dhaygude1, J. Lukac1, T. Ojala2, P. Mattila2, A. Nykänen1, K. Lemström1. 1Transplantation Laboratory, University of Helsinki, Helsinki, Finland, 2Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
2:15 PM	(163) Higher Intensity Statin Therapy Reduces Clinical Endpoints after Heart Transplantation Independent of Lipid Levels J. R. Golbus1, S. Adie1, S. Hanigan1, M. Dorsch1, B. Rooks2, K. D. Aaronson1, M. C. Konerman1. 1Internal Medicine, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI
2:30 PM	(164) Everolimus in the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy in Heart Transplantation (RAD-TAC Study) C. Anthony, M. Imran, S. Emmanuel, J. Iliff, E. Kotlyar, K. Muthiah, A. M. Keogh, C. S. Hayward, P. S. Macdonald, A. Jabbour. Heart and Lung Transplant, St Vincent's Hospital Sydney, Sydney, Australia
2:45 PM	(165) Gut Microbial Diversity, Inflammation and Oxidative Stress is Associated with Tacrolimus Dosing Requirements Early after Heart Transplant D. L. Jennings1, B. Bohn Damasceno Ferreira2, A. Zuver2, O. Drew3, M. Gaine3, E. Royzman3, J. Hupf3, M. Farr3, F. Latif3, S. Restaino3, A. R. Garan3, H. Takayama4, K. Takeda4, Y. Naka4, P. C. Colombo3, R. Demmer5, M. Yuzefpolskaya3. 1Pharmacy, NewYork-Presbyterian Hospital, New York, NY, 2Public Health, Columbia University, New York, NY, 3Medical Cardiology, Columbia University, New York, NY, 4Cardiothoracic Surgery, Columbia University, New York, NY, 5Public Health, University of Minnesota, Minneapolis, MN
3:00 PM	(166) Early Infection Risk Associated with Induction Immunosuppression after Cardiac Transplant in Patients with Left Ventricular Assist Devices J. Batra1, D. L. Jennings1, A. R. Garan1, L. K. Truby1, K. Takeda2, H. Takayama2, S. Restaino1, F. Latif1, J. Haythe1, M. Yuzefpolskaya1, P. C. Colombo1, Y. Naka2, M. A. Farr1, V. K. Topkara1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY
3:15 PM	(167) Specific Immune Tolerance Response Triggered by Extracorporal Photopheresis after Heart Transplantation K. Klaeske1, M. Dieterlen1, J. Wittke1, M. Borger1, J. Garbade1, S. Lehmann1, H. Reichenspurner2, M. Barten2. 1Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany, 2University Heart Center Hamburg, Hamburg, Germany

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: HF/HTX
Secondary Audiences: MCS, PEDS

Session Summary: The aim of this symposium is to describe the pathophysiology and management of heart failure syndromes that are unique to ACHD patients.

Chairs: Maryjane Farr, MD and Heather Ross, MD, MHSc, FRCPC
 

1:45 PM	Too Sick to Live, Too Well to Die: When Do You Transplant A Failing ACHD Patient? Daphne Hsu, MD, Children's Hospital Montefiore, Bronx, NY, USA
2:00 PM	Q&A
2:05 PM	Is Two Really Better Than One? Heart-Liver Transplantation in ACHD Clive J. Lewis, MB, BChir, PhD, FRCP, Papworth Hospital, Cambridge, United Kingdom
2:20PM	Q&A
2:25 PM	Under Pressure: Managing Pulmonary Hypertension in ACHD Robert Weintraub, MD, Royal Children's Hospital, Parkville, Australia
2:40PM	Q&A
2:45 PM	I've Got Options: VADs in Patients with ACHD David Morales, MD, Cincinnati Children's Hospital, Cincinnati, OH, USA
3:00 PM	Q&A
3:05 PM	The Failing Sub-Pulmonic RV in Congenital Heart Disease: Forgotten, But Not Gone Wendy M. Book, MD, Emory University, Atlanta, GA, USA
3:20 PM	Q&A

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS

Chairs: Nader Moazami, MD and Emma Birks, MD, PhD
 

1:45 PM	(168) Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: The RAMP-IT-UP Multicenter Study N. Uriel1, D. Burkhoff2, J. Rich3, S. Drakos4, D. Banerjee5, J. Teuteberg5, G. Sayer1. 1University of Chicago, Chicago, IL, 2Columbia University, New York, NY, 3Northwestern University, Chicago, IL, 4University of Utah, Salt Lake City, UT, 5Stanford University, Palo Alto, CA
2:00 PM	(169) HeartMate 3 Surgical Implant Technique and Outcomes in the MOMENTUM 3 Trial C. Salerno1, Y. Naka2, S. C. Silvestry3, D. J. Goldstein4, J. C. Cleveland5, A. Bansal6, N. A. Mokadam7, J. N. Schroder8, V. Jeevanandam9, A. J. Tatooles10, J. Chuang11, J. W. Long12. 1St. Vincent Heart Center, Indianapolis, IN, 2Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York, NY, 3Florida Hospital, Orlando, FL, 4Montefiore Einstein Center for Heart and Vascular Care, New York, NY, 5University of Colorado School of Medicine, Aurora, CO, 6Ochsner Clinic Foundation, New Orleans, LA, 7Ohio State University Medical Center, Columbus, OH, 8Duke University Medical Center, Durham, NC, 9University of Chicago School of Medicine and Medical Center, Chicago, IL, 10Advocate Christ Medical Center, Oak Lawn, IL, 11Abbott, Abbott Park, IL, 12Integris Baptist Medical Center, Oklahoma City, OK
2:15 PM	(170) Poor Left Ventricular Unloading is Associated with Increased Mortality after Continuous Flow Left Ventricular Assist Device Implantation V. Maharaj1, R. Cogswell1, J. Schultz1, R. John2, C. Martin1, T. Thenappan1, T. Alexy1. 1Division of Cardiology, University of Minnesota Medical Center, Minneapolis, MN, 2Division of Cardiothoracic Surgery, University of Minnesota Medical Center, Minneapolis, MN
2:30 PM	(171) Effect of Anesthesia on Cardiac Hemodynamics in patients undergoing durable LVAD Implantation: The EACH LVAD Study T. C. Hanff1, P. A. Patel2, K. L. Kurcik1, S. Rao1, S. E. Kimmel3, M. E. Putt3, P. Atluri4, C. A. Bermudez4, M. A. Acker4, E. Y. Birati1, J. E. Rame1, J. W. Wald1. 1Division of Cardiology, University of Pennsylvania, Philadelphia, PA, 2Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, 3Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 4Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA
2:45 PM	(172) Evaluation of Anticoagulation Bridging Strategies in LVAD Patients A. D. Rabon1, D. J. Taber2, W. E. Uber1, B. A. Houston3, H. Meadows1. 1Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, 2Department of Surgery, Medical University of South Carolina, Charleston, SC, 3Division of Cardiology, Medical University of South Carolina, Charleston, SC
3:00 PM	(173) Concentrated Factor Administration and Subsequent Pump Thrombosis on HeartMate II LVAD Support H. Shah1, R. Cogswell1, J. Misialek2, J. Schultz1, A. Nitzkowski3, R. John4, C. Martin1, M. Pritzker1, A. Shaffer4. 1Cardiology, University of Minnesota, Minneapolis, MN, 2Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, 3Pharmacology, University of Minnesota, Minneapolis, MN, 4Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN
3:15 PM	(174) Regional Outcomes after Continuous-Flow Left Ventricular Assist Device: An IMACS Analysis K. K. Mirza1, R. Rongbing Xie2, J. K. Kirklin2, B. Meyns3, J. A. Cowger4, J. Pennington2, F. Gustafsson1, D. Goldstein5. 1Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, 2Department of Surgery, University of Alabama, Birmingham, AL, 3Katholieke Universiteit Leuven, Leuven, Belgium, 4Henry Ford Hospital, Detroit, MI, 5Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS
Secondary Audience: NHSAH

Chairs: Gene H. Kim, MD and Mary E. Keebler, MD
 

1:45 PM	(175) Complete Sternal-Sparing LVAD Implantation is a Safe and Effective Technique for Obese Patients K. Wood, B. C. Ayers, H. Vidula, J. Alexis, B. Barrus, S. Prasad, I. Gosev. University of Rochester, Rochester, NY
2:00 PM	(176) Continuous-Flow Left Ventricular Assist Devices and Bariatric Surgery in Patients with Morbid Obesity and Heart Failure - A Systematic Review J. Challapalli1, D. Cross2, M. P. Weber2, J. Choi2, E. J. Maynes2, R. Aggarwal3, A. J. Boyle4, J. W. Entwistle2, H. T. Massey2, R. J. Morris2, V. Tchantchaleishvili2. 1College of Medicine, Drexel University, Philadelphia, PA, 2Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA, 3Department of Surgery, Thomas Jefferson University, Philadelphia, PA, 4Division of Cardiology, Thomas Jefferson University, Philadelphia, PA
2:15 PM	(177) Impact of Diabetes Mellitus on Mortality and In-Hospital Outcomes after Left Ventricular Assist Device Implantation V. Blumer1, M. Ortiz2, G. Hernandez3, S. Chaparro1, A. Vest4. 1University of Miami, Miami, FL, 2University of Iowa, Iowa, IA, 3Univ. of Miami, Miami, FL, 4Tufts Medical Center, Boston, MA
2:30 PM	(178) The Combination of Left Ventricular Assist Device and Laparoscopic Sleeve Gastrectomy May Promote Myocardial Recovery in Obese Advanced Chronic Heart Failure Patients G. Poglajen1, S. Kumar1, B. Akkanti1, R. Radovancevic1, S. Nathan1, M. Jumean1, M. H. Akay1, M. Patel1, B. Vrtovec2, B. Kar1, I. D. Gregoric1. 1Department of Advanced Cardiopulmonary Therapies and Transplantation, The Univ. of Texas Health Science Center-Houston, Houston, TX, 2Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljublijana, Slovenia
2:45 PM	(179) Comprehensive Nutrition Assessment before Left Ventricular Assist Device Implantation in Chronically Ill Hospitalized Patients A. Melehy, D. Seres, H. Mullen, J. Sanchez, P. Kurlanksy, R. Garan, V. Topkara, M. Yuzefpolskaya, P. C. Colombo, H. Takayama, Y. Naka, K. Takeda. Columbia University Medical Center, New York, NY
3:00 PM	(180) The Impact of Frailty on Survival in Patients Undergoing Advanced Therapies for Heart Failure M. Stein1, K. T. O'Brien1, F. Foroutan1, V. Rao1, H. J. Ross1, A. C. Alba2. 1Toronto General Hopsital, University Health Network, Toronto, ON, Canada, 2Toronto General Hospital, University Health Network, Toronto, ON, Canada
3:15 PM	(181) Frailty and Clinical Outcomes Following Left Ventricular Assist Device Implantation H. G. Uzun1, E. Demir2, E. Simsek2, T. Capanoglu3, H. Karapolat3, C. Engin4, T. Yagdi4, P. Ozturk4, M. Ozbaran4, S. Nalbantgil2. 1Cardiology, Can State Hospital, Canakkale, Turkey, 2Cardiology, Ege University, Izmir, Turkey, 3Physical Medicine and Rehabilitation, Ege University, Izmir, Turkey, 4Cardiovascular Surgery, Ege University, Izmir, Turkey

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: PH
Secondary Audiences: CTEPH, PATH

Session Summary: This symposium, in collaboration with the Pulmonary Vascular Research Institute (PVRI), will focus on controversies and new proposed developments under review since the recent World Symposium on Pulmonary Hypertension, exploring the concept of changing the definition to mean pulmonary artery pressure of 20mmHg and the implications for future management of patients, risk stratification of patients with PAH and best approach, and which best clinical trial endpoint should be adopted.

Chairs: Colin Church, MD, PhD and Marc A. Simon, MD
 

1:45 PM	Feeling the Pressure: New Hemodynamic Classification of Pulmonary Vascular Disease Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA
2:00 PM	Q&A
2:05 PM	The Drugs Don’t (or might not) Work Anymore! Implications for Treatments in PAH with the New Hemodynamic Definition Mardi Gomberg-Maitland, MD, Inova Fairfax Hospital, Falls Church, VA, USA
2:20 PM	Q&A
2:25 PM	Too Risky for PAH? Patient Stratification and Implications for Treatment Paul Hassoun, MD, Johns Hopkins University, Baltimore, MD USA
2:40 PM	Q&A
2:45 PM	DEBATE: Quality Over Quantity? Future Trial Primary Endpoints Should Be QOL Focused (PRO) Ioana R. Preston, MD, Tufts Medical Center, Boston, MA, USA
3:00 PM	DEBATE: Quality over Quantity? Future Trial Primary Endpoints Should be QOL Focused (CON) Ardeschir Ghofrani, MD, University of Giessen, Giessen, Germany
3:15 PM	Debate Rebuttal (PRO) - Ioana R. Preston, MD, Tufts Medical Center, Boston, MA, USA
3:20 PM	Debate Rebuttal (CON) - Ardeschir Ghofrani, MD, University of Giessen, Giessen, Germany

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: ALL

Chairs: Hermann Reichenspurner, MD, PhD and Christopher H. Wigfield, MD, FRCS
 

4:00 PM	(182) B Cells Drive Chronic Lung Allograft Rejection after Ischemia-Reperfusion Injury in Mouse Lung Transplantation T. Watanabe, T. Martinu, K. Boonstra, M. Horie, Z. Guan, B. Joe, K. Bei, A. Chruscinski, D. Hwang, M. Liu, S. Keshavjee, S. Juvet. University Health Network, Toronto, ON, Canada
4:15 PM	(183) Microbiome Dependent Regulatory T Cell Generation Correlates with Acute and Chronic Lung Allograft Rejection in a Murine Model Y. Guo1, Q. Wang1, D. Li1, A. Manafi1, Z. Mei1, O. Onyema1, A. E. Gelman2, D. Kreisel2, A. S. Krupnick1. 1Surgery, University of Virginia, Charlottesville, VA, 2Surgery, Washington University in St. Louis, St. Louis, MO
4:30 PM	(184) Right Ventricular Dysfunction Correlates with Decreased Endothelial Progenitor Cell Mobilisation and Impaired Angiogenesis in Patients with Dilated Cardiomyopathy S. Frljak1, M. Jaklic1, G. Zemljic1, A. Cerar1, G. Poglajen1, F. Haddad2, B. Vrtovec1. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA
4:45 PM	(185) Host miRNA Profile of Invasive Aspergillosis in Lung Transplant Recipients W. Gohir1, W. Klement2, L. G. Singer3, S. M. Palmer4, S. Keshavjee3, S. Husain1. 1Multi Organ Transplant Unit, Division of Infectious Diseases, University Health Network, Toronto, ON, Canada, 2Organ Donation and Transplantation, Canadian Blood Services, Ottawa, ON, Canada, 3Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 4Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC
5:00 PM	(186) Estimation of Pulmonary Capillary Wedge Pressure from the HVAD Waveform and Its Prognostic Implications T. Imamura, D. Nitta, D. Rodgers, J. Grinstein, S. Kalantari, B. Smith, J. Raikhelkar, G. Kim, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, T. Fujino, C. Juricek, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
5:15 PM	(187) Hemodynamic Parameters That Predict Success with an Ambulatory Counterpulsation Heart Assist System in Advanced Congestive Heart Failure T. Symalla1, T. Song1, D. Onsager1, T. Ota1, C. LaBuhn1, P. Combs1, T. Lammy1, S. Patel-Raman2, G. Sayer3, G. Kim3, J. Raikhelkar3, N. Uriel3, V. Jeevanandam1. 1Cardiac Surgery, University of Chicago, Chicago, IL, 2NuPulseCV, NuPulseCV, Chicago, IL, 3Cardiology, University of Chicago, Chicago, IL
5:30 PM	(188) A Novel Tool to Quantify Immune Suppression after Pediatric Transplantation: Flow Cytometric Activation Assays R. E. Penner1, L. Ionescu1, S. Mital2, B. Foster3, P. Birk4, V. Phan5, T. Blydt-Hansen6, U. Allen2, L. Hamiwka7, C. Morgan1, S. Urschel1. 1University of Alberta, Edmonton, AB, Canada, 2Hospital for Sick Children, Toronto, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Manitoba, Winnipeg, MB, Canada, 5CHU Sainte-Justine, Montreal, QC, Canada, 6BC Children's Hospital, Vancouver, BC, Canada, 7Alberta Children's Hospital, Calgary, AB, Canada

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: HF/HTX
Secondary Audience: BSTR, PATH

Chairs: David Schibilsky, MD and Ravikumar Ratnagiri, MD
 

4:00 PM	(189) Clinical and Pathological Insights of Myocardial Molecular Profiling: Time to Revise ISHLT Grading System L. Potena1, V. Agostini1, L. Borgese1, E. Rinaldi1, L. Giovannini1, J. Reeve2, M. Parkes2, M. Masetti1, A. Russo1, O. Leone1, P. Halloran2. 1Bologna University Hospital, Bologna, Italy, 2University of Alberta, Edmonton, AB, Canada
4:15 PM	(190) HLA Epitope Mismatching is Associated with Rejection and Worsened Graft Survival in Heart Transplant Recipients E. Osorio-Jaramillo1, G. W. Haasnoot2, A. Kaider3, A. Zuckermann1, A. Schaefer1, T. Haberl1, J. Goekler1, P. Angleitner1, R. Moayedifar1, G. F. Fischer4, G. Laufer1, F. H. Claas2, A. Z. Aliabadi-Zuckermann1. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Immunhematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, 3Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 4Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
4:30 PM	(191) Non-HLA Antibodies as a Cause for Biopsy Negative Rejection: Is It Worth Testing for Them? J. A. Kobashigawa1, J. Patel1, M. Kittleson1, E. Kransdorf1, S. Dimbil1, R. Levine1, G. Esmailian1, C. Kawata1, L. Czer1, M. Hamilton1, D. Ramzy1, X. Zhang2. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
4:45 PM	(704) Heart Transplant Patients with Histologic Normal and Molecular Microscope Abnormal Biopsies: An Exploratory Analysis K. Shah1, J. A. Kobashigawa1, J. Patel1, M. Kittleson1, D. H. Chang1, S. Dimbil1, R. Levine1, S. Sana1, L. Czer1, B. Azarbal1, F. Esmailian1, P. Halloran2. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2University of Alberta, Alberta, AB, Canada
5:00 PM	(193) Racial Differences in Risk of Acute Rejection after Cardiac Transplantation R. C. Patel1, L. B. Cooper2, R. T. Cole3, S. Sinha2, L. J. Bogar4, S. D. Barnett2, A. Cochrane2, M. Psotka2, P. Shah2. 1Virginia Commonwealth University School of Medicine, Richmond, VA, 2Department of Heart Failure and Transplant, Inova Heart and Vascular Institute, Falls Church, VA, 3Department of Heart Failure and Transplant, Emory University, Atlanta, GA, 4Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA
5:15 PM	(194) Crossing Low Level Donor-Specific Antibody at the Time of Heart Transplantation May Save Lives J. A. Kobashigawa1, M. Kittleson1, D. H. Chang1, E. Kransdorf1, S. Dimbil1, R. Levine1, C. Kawata1, M. Olymbios1, A. Velleca1, L. Czer1, X. Zhang2, D. Ramzy1, J. Patel1. 1Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA
5:30 PM	(195) Identification of Risk Factors for Biopsy-Proven Rejection during the First Year Post Heart Transplantation G. Coutance1, G. Bonnet2, J. Van Keer3, M. Racapé3, P. Bruneval2, J. Duong Van Huyen3, J. Taupin4, S. Varnous5, L. Lecuyer6, P. Rouvier5, X. Jouven2, A. Loupy3. 1Paris Transplant Group, Pitié-Salpêtrière Hospital, Paris, France, 2Paris Transplant Group, Hôpital Européen Georges Pompidou, Paris, France, 3Paris Transplant Group, Paris, France, 4Saint Louis Hospital, Paris, France, 5Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 6Hôpital Européen Georges Pompidou, Paris, France

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: ID
Secondary Audiences: LF/LTX, PATH, PHARM

Session Summary: Fungal infections after thoracic transplantation are associated with high mortality. Prophylaxis and treatment come with various complications including drug-drug interactions, toxicities, treatment failure and emerging resistance. This symposium will provide insights regarding the epidemiology, prevention, diagnosis and treatment approaches to take when faced with the challenges of fungal infections in thoracic transplantation.

Chairs: Orla Morrissey, MD and Gregory A. Fishbein, MD
 

4:00 PM	Defining Fungal Infection: Not a TRIVIAL PURSUIT Erika D. Lease, MD, University of Washington, Seattle, WA, USA
4:15 PM	DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (PRO) John W. Baddley, MD, MSPH, University of Alabama at Birmingham, Birmingham, AL, USA
4:30 PM	DEBATE: Every Patient Should Receive Antifungal Prophylaxis After Lung Transplantation (CON) Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
4:45 PM	Don’t Be SORRY! Tips and Tricks for Managing Azole Antifungal Agents Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA
5:00 PM	Not a MONOPOLY: Antifungal Drug Administration Via the Inhaled Route Antonio B. Roman, MD, PhD, Hospital General Vall D'Hebron, Barcelona, Spain
5:15 PM	Are We in TROUBLE? Emergence of Azole-Resistant Molds Minh-Hong Nguyen, MD, University of Pittsburgh, Pittsburgh, PA, USA
5:30 PM	15-min Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS
Secondary Audience: BSTR, PATH

Chairs: Ahmet Kilic, MD and Carlo Banfi, MD, PhD, FCCP
 

4:00 PM	(196) Evaluation of the Effect of Artificial Pulsatility in Continuous Flow Assist Device on Peripheral Vascular Reactivity P. Ivak1, J. Pi'ha2, P. Wohlfahrt2, I. Kralova-Lesna2, V. Lanska3, Z. Tucanova1, M. Konarik1, I. Netuka1. 1Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 3Department of Data Analysis and Statistics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
4:15 PM	(197) Long-Term Changes in Kidney Function after Left Ventricular Assist Device Implant: An Analysis of the STS Intermacs Database D. D. Franz1, M. R. Stedman1, S. L. Myers2, D. C. Naftel2, S. A. Silver3, D. Banerjee1, T. I. Chang1. 1Medicine, Stanford University, Palo Alto, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Kingston General Hospital, Kingston, ON, Canada
4:30 PM	(198) Functional Assessment of Decellularized Extracellular Matrix in Patients Undergoing LVAD Implantation D. Yu1, M. Vaicik2, A. Nguyen1, D. Rodgers1, N. Narang1, H. Holzhauser1, I. Ebong1, A. Kanelidis1, G. Sayer1, J. Raikhelkar1, N. Sarswat1, B. Smith1, S. Kalantari1, B. Chung1, J. Georgiadis2, N. Uriel1, G. H. Kim1. 1Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL, 2College of Engineering, Illinois Institute of Technology, Chicago, IL
4:45 PM	(199) Platelet Transcriptomics Following Mechanical Unloading A. Koliopoulou, C. Frey, E. Montenont, J. W. Rowley, S. H. McKellar, S. G. Drakos, M. T. Rondina, C. H. Selzman. University of Utah, Salt Lake City, UT
5:00 PM	(200) A Comparison of Middle Cerebral Artery and Central Retinal Artery Hemodynamics in HM II Patients E. J. Stöhr1, R. Ji2, K. Akiyama3, F. Castagna2, A. Pinsino2, J. R. Cockcroft1, M. Yuzefpolskaya2, A. R. Garan2, V. K. Topkara2, R. T. Te-Frey3, H. Takayama3, K. Takeda3, Y. Naka3, P. C. Colombo2, J. Z. Willey4, B. J. McDonnell1. 1Physiology & Health, Cardiff Metropolitan University, Cardiff, United Kingdom, 2Medicine, Columbia University Medical Center, New York, NY, 3Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 4Neurology Stroke, Columbia University Medical Center, New York, NY
5:15 PM	(201) Risk of dnDSA with Various MCS Devices as Bridge-to-Transplant R. T. Cole1, M. Flattery2, J. Minto3, A. Parikh4, T. Dong1, R. Roy1, L. Bogar5, A. Smith1, J. Vega1, A. Morris1, S. Laskar6, K. Bhatt1, D. Gupta1, A. Lala7, K. Shah8, P. Shah9. 1Cardiology, Emory Univ Sch of Med, Atlanta, GA, 2Cardiology, Virginia Commonwealth University, Richmond, VA, 3George Washington University School of Medicine, Washington, D.C., DC, 4Cardiology, Mount Sinai Hospital, New York, NY, 5Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, 6Cardiology, Emory University School of Medicine, Atlanta, GA, 7Mount Sinai Hospital, New York, NY, 8Virginia Commonwealth University, Richmond, VA, 9Inova Heart and Vascular Institute, Falls Church, VA
5:30 PM	(202) Associations among Biomarkers of Congestion, Inflammation and Oxidative Stress in Heart Failure, LVAD and Heart Transplant E. A. Royzman1, G. M. Mondellini1, A. M. Zuver1, C. A. Bravo2, D. L. Brunjes1, D. Onat1, M. Mabasa1, J. C. Hupf1, A. R. Garan1, H. Takayama3, K. Takeda3, Y. Naka3, R. T. Demmer4, P. C. Colombo1, M. Yuzefpolskaya1. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Department of Medicine, Montefiore Medical Center, Bronx, NY, 3Department of Surgery, Columbia University Medical Center, New York, NY, 4Epidemiology and Community Health, University of Minnesota, Minneapolis, MN

Visit the ISHLT2019 Online Program Viewer to see the full details for this session

Primary Audience: MCS

Session Summary: Following a brief update on the state of the art of short and long term MCS, this symposium will focus on innovation and improvement opportunities. Specifically, issues of device size, deployment / implantation, hemodynamic properties and hemocompatibility will be reviewed. Presenters will discuss current capabilities as well as ongoing research and development efforts with 2- and 5-year targets. This symposium is not CME accredited.

Chairs: Ulrich Jorde, MD and Simon Maltais, MD, PhD
 

4:00 PM	STATE OF THE ART Durable MCS and Unmet Needs Joseph G. Rogers, MD, Duke University Medical Center, Durham, NC, USA
4:05 PM	The Future of Durable MCS - Medtronic Perspective Eric Corndorf, PhD, Medtronic, Framingham, MA, USA
4:20 PM	The Future of Durable MCS - Abbott Perspective Kevin Bourque, DVP, Abbott, Burlington, MA, USA
4:35 PM	STATE OF THE ART and Unmet Needs Total Heart Replacement (THR) Julia Riebandt, MD, Medical University of Vienna, Vienna, Austria
4:40 PM	The Future of THR - Syncardia Perspective Steven R. Langford, BSEE, SynCardia Systems, Tucson, AZ, USA
4:55 PM	The Future of THR - Carmat Perspective Piet G. Jansen, MD, PhD, Carmat SA, Velizy-Villacoublay Cedex, France
5:10 PM	STATE OF THE ART Acute MCS and Unmet Needs Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
5:15 PM	The Future of Acute MCS - Abiomed Perspective Daniel H. Raess, MD, FACC, FACS, Abiomed, Danvers, MA, USA
5:30 PM	Panel Discussion

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: NHSAH
Secondary Audience: HTX, LTX, PEDS, PHARM

Chairs:Flavio R. Epstein, PhD and Melissa Sanchez, BScHons, PGDip, MSc, DClinPSy
 

4:00 PM	(203) Intravenous Methamphetamine Does Not Appear to Be a Contraindication for Heart Donation in Heart Transplantation A. Velleca, T. Kao, B. Kearney, J. Patel, M. Kittleson, R. Levine, S. Dimbil, S. Mersola, M. Hamilton, F. Esmailian, J. Kobashigawa. Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA
4:15 PM	(204) Donor Family and Recipient Anonymity: Time for Change J. Poole1, M. Shildrick2, S. Abbey3, I. Bachmann4, A. Carnie5, D. Dal Bo4, E. De Luca6, T. El-Sheikh7, E. Jan4, P. McKeever8, A. Wright9, H. Ross6. 1Faculty of Community Services, School of Social Work, Ryerson University, Toronto, ON, Canada, 2Tema Genus, Tema Institute, Linkopings Universitet, Linkopings, Sweden, 3Department of Psychiatry, University Health Network, Toronto, ON, Canada, 4Department of Studio Arts, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada, 5Winchester School of Art, Southampton University, Winchester, United Kingdom, 6Department of Cardiology, University Health Network, Toronto, ON, Canada, 7Department of Art History, Faculty of Fine Arts, Concordia University, Montreal, QC, Canada, 8Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, 9Department of English, Linguistics and Cultural Studies, University of Westminster, London, United Kingdom
4:30 PM	(205) Universal Depression Screen of Ambulatory Cardiac Transplant Recipients is Feasible and Identifies a Subset of Patients That May Benefit from Mental Health Intervention L. Peters, L. Rosenthal, H. Monroe, M. Dierks, A. Ambardekar, C. McIlvennan. University of Colorado, Aurora, CO
4:45 PM	(206) Depressive Symptoms, Physical Activity, and Post-Transplant Outcomes: The ADAPT Prospective Study P. J. Smith, C. Frankel, D. Bacon, E. Bush, L. Snyder. Duke University Medical Center, Durham, NC
5:00 PM	(207) PTSD in Tx ICU Nurses M. Sanchez1, A. Simon2, D. Ford1. 1Psychological Medicine, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom, 2MCS and Cardiothoracic Transplantation, Royal Brompton & Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom
5:15 PM	(208) Illness Specific Anxiety Following Pediatric Heart Transplant A. D. McCormick, K. R. Schumacher, M. Zamberlan, K. Uzark, S. Yu, R. Lowery, N. Rottach, M. K. Cousino. Department of Pediatrics, Michigan Medicine, Ann Arbor, MI
5:30 PM	(209) The Value of Licensed Clinical Social Worker Pre-Implant Assessment in Predicting Non-Compliance in Durable Mechanical Circulatory Support Device Patients H. Barone1, M. Olman2, A. Fishman2, L. Olanisa2, C. Runyan1, J. Hajj1, N. Huie1, M. Lindsay1, E. Passano1, J. Kobashigawa1, J. Moriguchi1, R. Cole1, F. Esmailian1, J. Chung1, D. Ramzy1. 1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: PH
Secondary Audience: PHARM

Chairs: C. Dario Vizza, MD and Amresh Raina, MD
 

4:00 PM	(210) Treatment with Oral Treprostinil Delays Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension - Results from FREEDOM-EV V. F. Tapson1, C. J. Sanchez Diaz2, G. M. Bohns Meyer3, T. Pulido4, P. Sepulveda5, K. Y. Wang6, C. Q. Deng7, R. Grover7, D. Solum7, A. Ousmanou7, R. J. White8. 1Cedars Sinai, Los Angeles, CA, 2Unidad De Inv Clinica En Medicina, Monterrey, Mexico, 3Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Brazil, 4Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5Hospital San Juan De Dios, University of Chile, Santiago, Chile, 6Taichung Veterans General Hospital, Taichung, Taiwan, 7United Therapeutics, Research Triangle Park, NC, 8University of Rochester Medical Center, Rochester, NY
4:15 PM	(211) Risk Assessment in Functional Class (FC) II Pulmonary Arterial Hypertension (PAH) Patients: Comparison of Physician Gestalt with ESC/ERS-Guidelines and REVEAL 2.0 S. Sahay1, A. Tonelli2, T. Kung3, Z. Watson4, R. L. Benza5. 1Houston Methodist Hospital, Houston, TX, 2Cleveland Clinic, Cleveland, OH, 3Actelion Pharmaceuticals US, Inc., South San Francisco, CA, 4Putnam Associates, Boston, MA, 5Allegheny General Hospital, Pittsburgh, PA
4:30 PM	(212) Clinical Surrogates of Right Ventricular-Pulmonary Arterial Uncoupling C. G. Ireland1, R. L. Damico1, T. M. Kolb1, S. Mathai1, S. Zimmerman1, A. A. Shah1, M. Mukherjee1, F. Wigley1, P. M. Hassoun1, D. A. Kass1, R. J. Tedford2, S. Hsu1. 1The Johns Hopkins Hospital, Baltimore, MD, 2Medical University of South Carolina, Charleston, SC
4:45 PM	(213) Relationship between Race/Ethnicity and Survival in Patients with Pulmonary Arterial Hypertension (PAH) S. Medrek1, S. Sahay2, T. Kung3, C. Zhao3, A. E. Frost2. 1Division of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, 2Houston Methodist Hospital, Houston, TX, 3Actelion, South San Francisco, CA
5:00 PM	(214) Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study R. L. Benza1, J. R. Klinger2, H. A. Ghofrani3, P. Jansa4, E. Grünig5, D. Vizza6, M. M. Hoeper7. 1The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 2Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, 3University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany, 4Clinicial Department of Cardiology and Angiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Centre for Pulmonary Hypertension, Thorax Clinic at the University Hospital, Heidelberg, Germany, 6Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy, 7Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany
5:15 PM	(215) Long-Term Outcomes in Pulmonary Arterial Hypertension by Functional Class: A Meta-Analysis of Randomized Controlled Trials and Observational Registries N. H. Kim1, M. Fisher2, D. S. Poch1, C. Zhao3, M. Shah3, S. Bartolome4. 1University of California, San Diego, La Jolla, CA, 2Emory School of Medicine, Atlanta, GA, 3Actelion, South San Francisco, CA, 4University of Texas, Southwestern Medical Center, Dallas, TX
5:30 PM	(216) Beta Receptor Blockade Fails to Recover Ventricular Function Despite Increased Pre-Synaptic Sympathetic Nervous System Function in Experimental Pulmonary Arterial Hypertension J. Zelt, A. Ahmadi, J. Renaud, R. deKemp, R. Beanlands, L. Mielniczuk. University of Ottawa Heart Institue, Ottawa, ON, Canada

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Infectious Diseases (Gardenia 2)
(ID, HTX, LTX, MCS)   Poster Numbers: 765-794

Junior Faculty Clinical Case Reports: Heart Failure/Transplantation, Lung Failure/Transplantation (Banda Sea 1 & 2)
(HF/HTX, LF/LTX)   Poster Numbers: 1338-1442

Lung Transplantation (Adult) (Hibiscus 1 & 2)
(LTX)   Poster Numbers: 795-853, 1029

Mechanical Circulatory Support (Adult) (Timor Sea 1 & 2)
(MCS)   Poster Numbers: 854-943, 1100

Primary Audience: BSTR, HTX
Secondary Audience: PATH, PEDS

Chairs: Alexander M. Bernhardt, MD and Karl B. Lemstron, MD, PhD
 

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Basic Science and Translational Research)
6:00 PM	(429) Functional Assessment of DCD Hearts Following Normothermic Regional Perfusion Can Predict Post-Transplantation Contractility R. Ribeiro, J. S. Alvarez, E. Paradiso, F. Yu, M. B. Adamson, F. Foroutan, V. Bissoondath, M. Meineri, V. Rao, M. V. Badiwala. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada
6:05 PM	(430) Hi1a, an ASIC1a Inhibitor, Significantly Improves the Tolerance of Donor Allografts to Ischaemia in a Rodent Model of DCD Heart Transplantation S. E. Scheuer1, L. Gao2, M. Hicks1, H. Chew1, A. Doyle2, J. Villanueva2, A. Jabbour1, G. King3, P. Macdonald1, K. Dhital1. 1St Vincent's Hospital, Darlinghurst, Australia, 2Victor Chang Cardiac Research Institute, Darlinghurst, Australia, 3Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
6:10 PM	(431) In Vivo Resuscitation, Perfusion and Transplantation of a Porcine Cardiac Allograft Donated after Cardiac Death A. Grant1, R. R. Gonzalez2, A. Klima1, A. Badiye3, A. Gardiner4, M. Thomas5, I. hernandez Schulman6, J. Hare7, A. Ghodsizad2, M. Loebe2. 1Miami Transplant Institute University of Miami, Miami, FL, 2Surgery, Miami Transplant Institute University of Miami, Miami, FL, 3Cardiology, Miami Transplant Institute University of Miami, Miami, FL, 4Veterinary Resources, University of Miami, Miami, FL, 5Department Veterinary Resources, University of Miami, Miami, FL, 6Interdisciplinary Stem Cell Institute, Department of Medicine, Division of Nephrology, Katz Family Division of Nephrology and Hypertension, University of Miami Leonard M Miller School of Medicine, Miami, FL, 7Interdisciplinary Stem Cell Institute, Cardiovascular Division, University of Miami Leonard M Miller School of Medicine, Miami, FL
6:15 PM	(432) Conditioned Medium from Mesenchymal Stem Cells Protects Vascular Grafts of Brain-Dead Rats against In Vitro Ischemia/Reperfusion Injury S. Korkmaz-Icöz1, P. Zhou1, Y. Guo1, S. Loganathan1, P. Brlecic1, T. Radovits2, M. Ruppert1, A. A. Sayour1, M. Karck1, G. Szabó1. 1Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis University, Budapest, Hungary
6:20 PM	(433) Gene Expression in Ex Vivo Perfused Porcine Hearts: Identification of a Molecular Injury-Repair Response 1, N. Herbers1, S. Hatami2, M. Mengel1, J. Nagendran2, D. H. Freed2, span style="text-decoration: underline">B. Adam1. 1Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada, 2Department of Surgery, University of Alberta, Edmonton, AB, Canada
6:25 PM	(434) Ghrelin, a Novel Growth Hormone-Releasing Peptide, Inhibits Inflammatory Response and Apoptosis during Ischemic Reperfusion Injury Following Murine Heart Transplantation N. Fukunaga1, R. V. Ribeiro1, V. Bissoondath1, F. Billia2, M. V. Badiwala1, V. Rao1. 1Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada
Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Heart Transplantation)
6:30 PM	(435) Survival Outcomes in Heart Transplant Patients; Specific Focus on ACHD Patients and Their Outcomes as Compared to Dilated and Ischemic Cardiomyopathy Patients A. Kinsella1, V. Rao1, C. Fan2, C. Manlhiot2, J. Stehlik2, H. Ross2, A. C. Alba2. 1Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, 2Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada
6:35 PM	(436) Candidate Selection and the Survival Benefit of Heart Transplantation in the United States W. F. Parker1, E. S. Huang1, R. D. Gibbons2, A. S. Anderson3, M. M. Churpek1. 1University of Chicago Medicine, Chicago, IL, 2Public Health Sciences, University of Chicago Medicine, Chicago, IL, 3Northwestern Medicine, Chicago, IL
6:40 PM	(437) Does Pre-Existing Donor Heart Coronary Artery Disease Impact Survival after Orthotopic Heart Transplantation? J. Jahanyar1, J. M. Liao2, N. Zhang3, R. J. Butterfield III4, B. W. Hardaway5, R. L. Scott5, E. D. Steidley5. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Health Sciences Research, Mayo Clinic, Phoenix, AZ, 4Biostatistics, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ
6:45 PM	(438) Long-Term Survival after Heart Transplantation: Interaction between Donor and Recipient Age A. Lechiancole, S. Sponga, V. Ferrara, C. Nalli, C. Di Nora, G. Guzzi, D. Piani, M. Meneguzzi, G. Benedetti, V. Tursi, U. Livi. Cardio-Thoracic Surgery of Udine, ASUIUD, Udine, Italy
6:50 PM	(982) Heart Transplantation with ECMO Bridging: Survival Differences in the Era of the New Heart Allocation Policy J. Jahanyar1, J. M. Liao2, N. Zhang3, R. J. Butterfield III4, B. W. Hardaway5, R. L. Scott5, E. D. Steidley5. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Medicine, University of Washington, Seattle, WA, 3Health Sciences Research, Mayo Clinic, Phoenix, AZ, 4Biostatistics, Mayo Clinic, Phoenix, AZ, 5Cardiology, Mayo Clinic, Phoenix, AZ
6:55 PM	(440) Survival after Primary Graft Dysfunction in Heart Transplantation: Outcomes of the National UK Data S. Avtaar Singh1, S. Das De1, S. Rushton2, N. Banner3, C. Berry4, N. Al-Attar1. 1Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, 2Statistics, National Health Service Blood and Transplant, Bristol, United Kingdom, 3Advanced Heart Failure and Transplantation, Harefield Hospital, London, United Kingdom, 4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: LF/LTX

Chairs: David R. Darley, MBBS, Bc(Hons II) and Erika D. Lease, MD

 

6:00 PM	(441) The Accuracy of LAS in Predicting Post-Transplant Risk of ECMO Recipients J. Katsis, W. F. Parker, M. Churpek, E. Garrity. Pulmonary and Critical Care, University of Chicago, Chicago, IL
6:05 PM	(442) The Protective Effect of Prone Positioning on Human Rejected Donor Lungs during Cellular Ex Vivo Lung Perfusion H. Niikawa1, T. Okamoto1, K. S. Ayyat1, Y. Itoda1, C. F. Farver2, K. R. McCurry1. 1Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 2Anatomic Pathology, Cleveland Clinic, Cleveland, OH
6:10 PM	(443) Evaluation of the Effects of the Correction of Hydroelectrolytic Disorders during Prolonged Ex-Vivo Lung Perfusion J. Issard, B. Decante, J. Guihaire, D. Mitilian, D. Boulate, S. Mussot, D. Fabre, E. Fadel, O. Mercier. Thoracic and Vascular Surgery, Hopital Marie Lannelongue, Paris, France
6:15 PM	(444) Donor Lung Weight at Lung Procurement; Predictive Value for Transplant Suitability during Ex Vivo Lung Perfusion T. Okamoto, H. Niikawa, D. Wheeler, B. Soliman, K. S. Ayyat, Y. Itoda, K. R. McCurry. Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
6:20 PM	(445) Impact of Lung Allograft Oversizing on Pleural Cavity Expansion in Transplant Recipients with Idiopathic Pulmonary Fibrosis S. H. Roberts1, S. L. Miter1, B. Shukrullah2, B. C. Keller1, M. E. Lee1, T. Yurjevic1, S. Carter1, A. Pope-Harman1, P. Lee1, B. A. Whitson1. 1The Ohio State University Wexner Medical Center, Columbus, OH, 2Minneapolis Heart Institute, Minneapolis, MN
6:25 PM	(446) Single Lung Transplant Compared with Double Lung Transplant in Older Adults with Interstitial Lung Disease L. J. Benvenuto1, M. Aversa1, L. Shah1, M. Carroll1, F. D'Ovidio2, B. P. Stanifer2, J. R. Sonett2, H. Y. Robbins1, S. Arcasoy1. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY
6:30 PM	(447) Right Single and Double Lung Transplant Outperform Left Single Lung Transplant in Chronic Obstructive Pulmonary Disease: A UNOS Analysis L. J. Benvenuto1, J. Costa2, D. Piloni2, M. Aversa1, H. Y. Robbins1, L. Shah1, B. P. Stanifer2, S. Arcasoy1, J. R. Sonett2, F. D'Ovidio2. 1Medicine, Columbia University Medical Center, New York, NY, 2Surgery, Columbia University Medical Center, New York, NY
6:35 PM	(448) Initial Experience with Non-Perfused Organ Donors for Lung Transplantation Y. Watanabe1, A. Healey2, M. Scott2, S. Lavery2, K. Johnson2, C. Mills2, M. Galasso1, M. Chen1, J. Yeung1, L. Donahoe1, A. Pierre1, M. de Perrot1, K. Yasufuku1, T. K. Waddell1, S. Keshavjee1, M. Cypel1. 1Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada, 2Trillium Gift of Life Network, Toronto, ON, Canada
6:40 PM	(449) Time from Lung Transplant Donor Brain Death to Cross Clamp: An Analysis of the UNOS Registry O. K. Jawitz, V. Raman, Y. Barac, M. Mulvihill, C. Moore, A. Choi, M. Hartwig, J. Klapper. Department of Surgery, Duke University School of Medicine, Durham, NC
6:45 PM	(450) Living-Donor Lobar Lung Transplantation with Undersized Lobar Grafts Can Provide Comparable Long-Term Pulmonary Function and Exercise Capacity to Cadaveric Lung Transplantation D. Nakajima, T. F. Chen-Yoshikawa, T. Menju, T. Sato, M. Sonobe, Y. Yamada, Y. Yutaka, A. Ohsumi, M. Hamaji, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan
6:50 PM	(451) Predicted Total Lung Capacity Ratio between Donors and Recipients Does Not Predict Outcomes in Non-Volume Reduced Lung Transplantation R. Poyanmehr1, W. Sommer1, F. Ius1, J. Salman1, T. Siemeni1, M. Avsar1, C. Kühn1, M. Greer2, J. Gottlieb2, T. Welte2, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Departement of Cardiothoracic Surgery, Medizinische Hochschule Hannover, Hannover, Germany, 2Departement of Pneumology, Medizinische Hochschule Hannover, Hannover, Germany
6:55 PM	(452) Human (Mesenchymal Stem Cells) SC Loaded Single Lung Allograft A. Grant1, R. R. Gonzalez2, N. Sinha3, B. Forsberg4, A. Klima4, A. Patel5, C. Piechazeck6, R. Vianna7, M. Mirsaeidi8, M. Loebe9, A. Ghodsizad10. 1Department of Surgery, Trauma and Surgical Critical Care Grady Memorial Hospital Emory University School of Medicine, Atlanta, GA, 2Surgery, Miami Transplant Institute University of Miami, Miami, FL, 3Miami Transplant Institute, Memorial Jackson Health System, University of Miami Leonard M Miller School of Medicine, Miami, FL, 4Comprehensive Care Services, Inc., Livonia, MI, 5Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 6Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, 7Department of Surgery, Liver, Intestinal and Multivisceral Transplant, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 8Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami Leonard M Miller School of Medicine, Miami, FL, 9Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL, 10Division of Heart and Lung Transplant and Mechanical Support, Miami Transplant Institute, Dewitt Daughtry Family Department of Surgery, Division of Cardiothoracic Surgery, University of Miami Leonard M Miller School of Medicine, Miami, FL

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session

Primary Audience: MCS

Chairs: Antonio Loforte, MD and Sanem Nalbantgil, MD
 

6:00 PM	(453) Early Anticoagulation Bridging to Therapeutic International Normalized Ratio after Left Ventricular Assist Device Implantation is Not Associated with Thromboembolic and Bleeding Complications: A Systematic Review and Meta-Analysis V. Kittipibul1, N. Angsubhakorn2, J. Kewchareon3, N. Prasitlumkum3, P. Rattanawong3. 1Department of Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, 2Department of Internal Medicine, University of Minnesota, Minneapolis, MN, 3Department of Internal Medicine, University of Hawaii, Honolulu, HI
6:05 PM	(454) Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices P. Namdaran1, T. A. Zikos2, J. Y. Pan2, D. Banerjee3. 1Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, 2Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, 3Division of Cardiovascular Medicine, Stanford University, Stanford, CA
6:10 PM	(917) HVAD Cannula Positioning is Associated with Higher GI Bleed Rates T. Imamura, G. Kim, J. Raikhelkar, B. Smith, A. Nguyen, N. Narang, B. Chung, I. Ebong, L. Holzhauser, D. Nitta, T. Fujino, C. Juricek, P. Combs, T. Song, T. Ota, V. Jeevanandam, G. Sayer, N. Uriel. University of Chicago, Chicago, IL
6:15 PM	(456) Diagnostic Yield of Endoscopy Procedures in the Management of Left Ventricular Assist Device Recipients Presenting with Gastrointestinal Bleeding A. Y. Lee1, K. M. Tecson2, H. E. Sheffield3, M. E. Marcom3, A. Z. Jacob3, S. Patlolla4, N. H. Kwak5, B. L. Da6, J. Felius7, S. A. Hall8, H. Kale9, P. Kale8. 1Baylor Heart and Vascular Hospital, Dallas, TX, 2Baylor Heart and Vascular Institute, Baylor Scott & White Research Institute, Dallas, TX, 3College of Medicine, Texas A&M Health Science Center, Dallas, TX, 4Department of Internal Medicine, Baylor Scott and White, Dallas, TX, 5Department of Gastroenterology, SUNY Health Science Center, Brooklyn, NY, 6National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, 7Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research Institute, Dallas, TX, 8Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott and White, Dallas, TX, 9Digestive Health Associates of Texas, Baylor Scott and White, Dallas, TX
6:20 PM	(457) Serotonergic Antidepressants and Hospitalization for Bleeding in Patients with LVAD K. Behrend1, M. P. Lillyblad1, P. Skelton1, R. F. Gaberich2, K. Wilson2, P. M. Eckman3, B. Sun3, K. Hryniewicz3. 1Abbott Northwestern Hospital, Minneaplis, MN, 2Minneapolis Heart Institute Foundation, Minneaplis, MN, 3Minneapolis Heart Institute, Minneaplis, MN
6:25 PM	(458) Correlation of Thromboelastography Parameters with Bleeding Episodes of Post-LVAD Surgery P. Tantrachoti, P. Pachariyanon, W. Vutthikraivit, B. Hirsch, N. Nair. Texas Tech University Health Sciences Center, Lubbock, TX
6:30 PM	(459) Safety and Performance of a Self-Assembling Peptide Haemostat for the Management of Bleeding after Left Ventricular Assist Device Implantation: Outcomes of a Post Market Clinical Follow-Up Study M. Morshuis, M. Schönbrodt, J. Gummert. Cardiac Surgery, HDZ-NRW.de, Bad Oeynhausen, Germany
6:35 PM	(460) Pre-Operative Ventilatory Inefficiency is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices M. D. Yu1, J. Newman1, Y. Brailovsky1, M. Liebo1, R. Zolty2, B. Lowes2, A. Heroux1, E. Raichlin1. 1Loyola University Medical Center, Maywood, IL, 2University of Nebraska Medical Center, Omaha, NE
6:40 PM	(461) Pulmonary Artery Pulsatile Index (PAPi) Score May Predict Risk of Gastrointestinal Bleeding in Patients with Left Ventricular Assist Device L. Cunningham, S. George, A. M. El Banayosy, D. Horstmanshof. Advanced Heart Failure and Transplant Cardiology, Integris Baptist Medical Center, Oklahoma City, OK
6:45 PM	(462) Gastrointestinal Hemorrhage among LVAD Recipients. A Nationwide Inpatient Sample Study D. C. Voruganti1, G. P. Shantha2, C. Inampudi3, P. Alvarez3, M. C. Giudici3, A. Briasoulis3. 1Internal Medicine, University of Iowa Hospitals and Clincs, Iowa City, IA, 2Cardiovascular Diseases, University of Michigan, Ann Arbor, MI, 3Cardiovascular Diseases, University of Iowa Hospitals and Clincs, Iowa City, IA
6:50 PM	(463) Microbiome-Derived TMAO Exhibits No Protective Effect against GIB in LVAD Patients A. M. Zuver1, K. L. Hoffman2, D. D'Angelo2, D. Onat1, E. A. Royzman1, J. C. Hupf1, D. L. Brunjes1, G. M. Mondellini1, C. A. Bravo3, M. Tiburcio4, A. R. Garan1, H. Takayama4, K. Takeda4, Y. Naka4, P. C. Colombo1, R. T. Demmer5, M. Yuzefpolskaya1. 1Department of Medicine, Columbia University Medical Center, New York, NY, 2Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, 3Department of Medicine, Montefiore Medical Center, Bronx, NY, 4Department of Surgery, Columbia University Medical Center, New York, NY, 5Epidemiology and Community Health, University of Minnesota, Minneapolis, MN
6:55 PM	(464) Gastrointestinal Bleeding Ceases after Heart Transplantation in Patients Bridged on Continuous-Flow LVAD Support A. Critsinelis1, J. Kraus2, H. Lamba1, F. Cheema1, A. Civitello1, R. Delgado1, A. Nair1, A. Shafii1, G. Loor1, T. Rosengart1, O. Frazier1, J. Morgan1. 1Division of Cardiothoracic Transplantation and Mechanical Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine, Houston, TX

Primary Audience: NHSAH, PHARM
Secondary Audience: HTX, LTX, PEDS

Chairs: Donna Hickling and Kyle Dawson, PharmD, MBA, BCPS
 

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Nursing, Health Sciences and Allied Health)
6:00 PM	(465) Associations between Self-Reported Physical Function and Exercise Capacity in De Novo Heart Transplant Recipients K. Rolid1, A. K. Andreassen1, M. Yardley1, E. Gude1, E. Bjørkelund1, A. R. Authen1, I. Grov1, K. I. Pettersen1, C. Dall2, E. Prescott2, K. Karason3, L. Gullestad1, K. Nytrøen1. 1Department of Cardiology, Oslo University Hospital,Rikshospitalet, Oslo, Norway, 2Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden
6:05 PM	(466) Effect of High Intensity Interval Training on Health Related Quality of Life in De Novo Heart Transplant Recipients-The HITTS Study K. Rolid1, A. K. Andreassen1, M. Yardley1, E. Gude1, E. Bjørkelund1, A. R. Authen1, I. Grov1, K. I. Pettersen1, C. H. Dall2, E. Prescott2, K. Karason3, L. Gullestad1, K. Nytrøen1. 1Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark, 3Department of Cardiology, Sahlgrenska University Hospital, Gothenborg, Sweden
6:10 PM	(467) Pre Transplant Quadriceps Strength is a Modifiable Predictor of Functional Outcomes Following Lung Transplantation J. R. Walsh1, D. C. Chambers2, S. T. Yerkovich2, N. R. Morris3, P. M. Hopkins2. 1Physiotherapy, The Prince Charles Hospital, Brisbane, Australia, 2Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, 3School of Allied Health Sciences, Griffith University, Gold Coast, Australia
6:15 PM	(468) What Happens to Frailty in the First Year after Lung Transplantation? L. M. Fuller1, H. Whitford2, Y. Cristiano2, R. Robinson1, R. Steward1, M. Poulsen1, W. Shi3, G. M. Snell4. 1Physiotherapy, Alfred Hospital, Melbourne, Australia, 2Respiratory Unit, Alfred Hospital, Melbourne, Australia, 3Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia, 4Lung Transplant Unit, Alfred Hospital, Melbourne, Australia
6:20 PM	(469) QOLVAD Detects Changes in Emotional, Social, Cognitive and Physical Wellbeing after Continuous-Flow LVAD Implant J. A. Cowger1, C. S. Lee2, P. Eckman3, R. Garberich4, C. Weaver5, S. Joseph6, S. Hall6, S. Carrie7, S. Chaudhry8, S. E. Schroeder9, R. O. Hoffman, III10, D. Feldman11, G. Conway12, E. Y. Birati13, M. Soni14, J. Marble15, K. M. Faulkner2, K. E. Sandau16. 1Cardiovascular Medicine, HF/Transplant/MCS, Henry Ford Hospital, Detroit, MI, 2Boston College Connell School of Nursing, Boston, MA, 3Cardiovascular Medicine, HF/Transplant/MCS, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 4Minneapolis Heart Institute Foundation, Minneapolis, MN, 5Cardiovascular Medicine, HF/Transplant/MCS, Abbott Northwestern Hospital/Minneapolis Heart Institute, Minneapolis, MN, 6Cardiovascular Medicine, HF/Transplant/MCS, Baylor University Medical Center, Dallas, TX, 7Baylor University Medical Center, Dallas, TX, 8Cardiovascular Medicine, HF/Transplant/MCS, Ascension Hospital/St Vincent, Indianapolis, IN, 9Bryan Heart Center, Lincoln, NE, 10University of Cincinnati Medical Center, Cincinnati, OH, 11Cardiovascular Medicine, HF/Transplant/MCS, University of Cincinnati Medical Center, Cincinnati, OH, 12Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, Cincinnati, OH, 13Cardiovascular Medicine, HF/Transplant/MCS, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA, 14Department of Medicine, University of Pennsylvania, Philidelphia, PA, 15Cardiovascular Medicine, HF/Transplant/MCS, University of Pennsylvania, Philidelphia, PA, 16Cardiovascular Medicine, Bethel University; Allina Health, Minneapolis, MN
6:25 PM	(470) Lack of Social Support is Not a Contraindication to VAD Therapy N. Robinson Smith1, E. Sowerby2, J. Meadows2, S. Tovey Brown3, A. Woods1, G. MacGowan1, S. Schueler1. 1MCS Service Cardio Thoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, 2Social Work, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom, 3MCS Service Cardiothoracic, Newcastle upon Tyne Hospital NHS Trust, Newcastle upon Tyne, United Kingdom
6:30 PM	(471) It Takes a Village: Pediatric Ventricular Assist Device Training and Education Practices among ACTION Centers K. Fields1, B. Hawkins2, J. Lantz3, M. Mehegan4, J. Murray5, L. Burkhart1, C. Villa1. 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Boston Children's Hospital, Boston, MA, 3Children's Medical Center Dallas, Dallas, TX, 4St. Louis Children's Hospital, Saint Louis, MO, 5Lucille Packard Children's Hospital, Palo Alto, CA
6:35 PM	(472) Lung Transplant Clinicians’ Perceptions of Pocket PATH Synergy, an Interactive Health Technology (IHT) to Monitor Patients Remotely A. J. Devito Dabbs1, T. Irizarry1, M. Alrawashdeh1, J. M. Pilewski2, M. Morrell2, J. D'Cunha2, M. Dew2. 1University of Pittsburgh School of Nursing, Pittsburgh, PA, 2University of Pittsburgh School of Medicine, Pittsburgh, PA
6:40 PM	(473) Pre-Lung Transplant Waitlist Mortality Rate Reduction Using Remote Video Monitoring Technology M. Zubrinic1, N. Marks2, L. Brzozowski3, J. Qiu3, D. Lin3, K. Wang3, J. De Romana1, L. Singer4, S. Keshavjee1. 1Department of Surgery, University Health Network, Toronto, ON, Canada, 2Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 3Techna Institute & University Health Network, Toronto, ON, Canada, 4Division of Respirology, Department of Medicine, University Health Network, Toronto, ON, Canada
Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Pharmacy and Pharmacology)
6:45 PM	(474) A Pilot Randomized Placebo Controlled Trial of Inhaled Beclomethasone after Community-Acquired Respiratory Viral (CARV) Infection in Lung Transplant Recipients (LTR) K. B. Bain1, K. A. Fester1, J. Iuppa2, K. Bakos1, B. Mittler3, K. Richardson3, P. Aguilar3, J. Alexander-Brett3, D. Byers3, H. Kulkarni3, E. Trulock3, C. Witt3, R. Yusen3, V. Puri4, D. Kreisel4, R. Hachem3. 1Pharmacy, Barnes Jewish Hospital, Saint Louis, MO, 2Pharmacy, University of Rochester Medical Center, Rochester, NY, 3Pulmonary & Critical Care, Washington University, Saint Louis, MO, 4Surgery, Washington University, Saint Louis, MO
6:50 PM	(475) Effects of INR Variability and Time in the Therapeutic Range on the Rates of Gastrointestinal Bleeding in Patients Supported by Left Ventricular Assist Devices A. Mardis1, M. Freiter2, B. Mierzejewski2, M. Adams3. 1Department of Pharmacy, Palmetto Health, Columbia, SC, 2College of Pharmacy, University of South Carolina, Columbia, SC, 3Department of Family and Preventive Medicine, University of South Carolina College of Medicine, Columbia, SC
6:55 PM	(476) Appropriate Management of Drug Interactions Results in Safe Use of Hepatitis C Therapies in Heart Transplant Recipients K. Boyle, R. E. Fowler, A. Pollack, C. Edmonds, J. Gray, J. Lindenfeld, K. Schlendorf. Vanderbilt University Medical Center, Nashville, TN

Primary Audience: PEDS, HF
Secondary Audience: LTX

Chairs: Jennifer Conway, MD and Tomasz Zielinski, MD
 

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Pediatrics)
6:00 PM	(477) Genetic Testing Outcomes in Pediatric Dilated Cardiomyopathy R. Khan1, E. Pahl1, L. Dellefave-Castillo2, K. Rychlik1, E. McNally2, G. Webster1. 1Cardiology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, 2Cardiology, Northwestern Memorial Hospital, Chicago, IL
6:05 PM	(478) Cardiac Resynchronization Therapy in Congenital Heart Disease and Pediatric Patients with Heart Failure is Associated with Improved Survival H. Chubb1, C. S. Almond2, D. N. Rosenthal2, A. V. Trela2, D. Hanisch2, K. S. Motonaga2, S. R. Ceresnak2, D. B. McElhinney2, A. M. Dubin2. 1Stanford University, Palo Alto, CA, 2Pediatric Cardiology, Stanford University, Palo Alto, CA
6:10 PM	(479) A Simple Pediatric Heart Failure Symptom Score for Children Hospitalized with Acute Decompensated Heart Failure C. S. Almond, D. Rosenthal, J. Kwong, J. Dykes, V. Yarlagadda, S. Chen, C. Chen. Stanford University, Palo Alto, CA
6:15 PM	(480) Distinction of Serum Biomarker Profiles between Adults and Children with Dilated Cardiomyopathy M. R. Gropler1, K. J. Lavine2, S. E. Lipshultz3, J. D. Wilkinson4, S. Colan5, J. Towbin6, L. Si7, C. E. Canter1, K. E. Simpson1. 1Pediatrics, Washington University in Saint Louis School of Medicine, St Louis, MO, 2Medicine, Washington University in Saint Louis School of Medicine, St Louis, MO, 3Pediatrics, Wayne State University School of Medicine, Detroit, MI, 4Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, 5Pediatrics, Harvard Medical School, Boston, MA, 6Pediatrics, University of Tennessee Health Science Center, Memphis, TN, 7New England Research Institute, Watertown, MA
6:20 PM	(481) Clinician Perspectives on the Potential Utility of a Patient Reported Outcomes Measure for Pediatric Heart Failure C. Chen, D. N. Rosenthal, S. Chen, J. C. Dykes, S. A. Hollander, C. S. Almond. Pediatric Cardiology, Stanford University, Palo Alto, CA
6:25 PM	(482) Broadening ABO Incompatibility Pediatric Heart Transplantation, Even in Children 2 Years and Older R. Daulton, K. Riggs, F. Zafar, C. Villa, R. Bryant, D. L. Morales. Cardiothoracic Surgery, Children's Hospital Med Ctr, Cincinnati, OH
Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Heart Failure)
6:30 PM	(483) Efficacy of Tafamidis in Patients with Hereditary or Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Results from the ATTR-ACT Trial M. Grogan1, R. Witteles2, S. J. Shah3, J. H. Schwartz4, B. Gundapaneni5, T. A. Patterson6, M. B. Sultan4, M. S. Maurer7. 1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Stanford University School of Medicine, Stanford, CA, 3Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Pfizer Inc, New York, NY, 5Department of Cardiovascular Diseases, Syneos Health, Raleigh, NC, 6Pfizer Inc, Groton, CT, 7Columbia University College of Physicians and Surgeons, New York, NY
6:35 PM	(484) The Rising Epidemic of Resource Utilization for Adult Congenital Heart Disease-Related Heart Failure in the United States D. S. Burstein1, J. W. Rossano1, H. Griffis1, X. Zhang1, R. Fowler2, B. P. Frischhertz2, Y. Y. Kim1, J. Lindenfeld2, J. A. Mazurek3, J. N. Menachem2. 1Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Cardiology, Vanderbilt University Medical Center, Nashville, TN, 3Cardiology, Hospital of University of Pennsylvania, Philadelphia, PA
6:40 PM	(970) Comparison of Long-Term Effects of Cell Therapy in Patients with Ischemic and Nonischemic Heart Failur G. Poglajen, G. Zemljic, S. Frljak, A. Cerar, M. Jaklič, B. Vrtovec. Advanced Heart Failure and Transplantation Center, University Medical Center Ljubljana, Ljubljana, Slovenia
6:45 PM	(486) Myocardial Ischemia Correlates with Left Ventricular Systolic Dysfunction in Patients with Noncompaction Cardiomyopathy A. Cerar1, M. Jaklic1, M. Dolenc Novak2, B. Guzic Salobir2, R. Zbacnik3, M. Kozelj1, B. Vrtovec1. 1Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, Slovenia, 3Department of Radiology, UMC Ljubljana, Ljubljana, Slovenia
6:50 PM	(487) Absence of Pre-Transplant Pulmonary Features of Sarcoidosis is of Low Negative Predictive Value in End-Stage Cardiac Sarcoidosis H. K. Rokadia1, A. K. Jamil2, R. El Tomi2, H. Zafar2, T. Nisar2, M. Petrozzi1, R. L. Gottlieb1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Scott & White Research Institute, Dallas, TX
6:55 PM	(488) Undiagnosed Cardiac Sarcoidosis Has a Significant First Presentation as Sudden Cardiac Death: An Autopsy Review D. Pedrotty1, A. Rosenbaum2, S. Kapa2, L. Blauwet2, J. Maleszewski3. 1Heart Failure Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Mayo Clinic, Rochester, MN, 3Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Primary Audience: PH, HTX

Chairs: John Granton, MD and Joanna Pepke-Zaba, MD
 

Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Pulmonary Hypertension)
6:00 PM	(489) Demographic, Hemodynamic, and HRQL Differences between Methamphetamine-Associated and Idiopathic PAH: The Pulmonary Hypertension Association Registry N. A. Kolaitis1, R. T. Zamanian2, V. A. de Jesus Perez2, D. B. Badesch3, R. L. Benza4, C. D. Burger5, M. M. Chakinala6, J. Feldman7, M. R. Lammi8, S. C. Mathai9, K. W. Presberg10, J. C. Robinson11, J. S. Sager12, O. A. Shlobin13, M. A. Simon14, S. M. Kawut15, J. P. Singer1, T. De Marco1. 1University of California, San Francisco, San Francisco, CA, 2Stanford University, Palo Alto, CA, 3University of Colorado Denver, Aurora, CO, 4Allegheny General Hospital, Pittsburgh, PA, 5Mayo Clinic Florida, Jacksonville, FL, 6Washington University in St. Louis, St. Louis, MO, 7Arizona Pulmonary Specialists, Phoenix, AZ, 8Louisiana State University, New Orleans, LA, 9Johns Hopkins University, Baltimore, MD, 10Medical College of Wisconsin, Milwaukee, WI, 11The Oregon Clinic, Portland, OR, 12Cottage Pulmonary Hypertension Center, Santa Barbara, CA, 13Inova Fairfax Medical Campus, Falls Church, VA, 14University of Pittsburgh, Pittsburgh, PA, 15University of Pennsylvania, Philadelphia, PA
6:05 PM	(490) Comparison of Outcomes of Living-Donor Lobar and Cadaveric Lung Transplantation in Patients with Pulmonary Arterial Hypertension S. Ueda, T. Chen-Yoshikawa, Y. Yokoyama, H. Oda, M. Ikeda, J. Tokuno, H. Kayawake, H. Yamagishi, F. Gochi, R. Okabe, D. Nakajima, A. Ohsumi, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
6:10 PM	(491) Do Pulmonary Hypertensive Patients Have Worse Post Transplant Survival Than Non-Pulmonary Hypertensive Patients? An ISHLT Registry Analysis J. Lasky1, K. Tsui2, C. Alex2, M. Dia2, E. Jweied2, P. Pappas2, C. Wigfield2. 1Rosalind Franklin University of Medicine and Science, Chicago, IL, 2Lung Transplant, Advocate Christ Medical Center, Chicago, IL
6:15 PM	(492) Exercise Pulmonary Hypertension and Progression to Resting Pulmonary Hypertension - Is TPR the Best Predictor? K. Kearney, N. Bart, V. Shah, P. Jain, E. Kotlyar, A. Keogh. St Vincents Hospital, Darlinghurst, Australia
6:20 PM	(1228) Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor M. Simon1, M. Gomberg-Maitland2, R. J. Oudiz3, R. Machado4, F. Rischard5, J. M. Elinoff6, B. Grigorian7, A. N. Schmid7, S. Hou7, N. Desai7, M. Gladwin1. 1Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, 2MSc. Inova Heart and Vascular Institute, VCU Medicine, Falls Church, VA, 3LA Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, 4Indiana University, Indianapolis, IN, 5Department of Medicine, University of Arizona, Tucson, AZ, 6The NIH Clinical Center, Bethesda, MD, 7Aadi Bioscience, Pacific Palisades, CA
6:25 PM	(495) Two Polymorphic Gene Loci Associated with Treprostinil Dose in Pulmonary Arterial Hypertension M. A. Psotka1, V. Thomeas-McEwing2, E. R. Gamazon3, T. Hirota4, P. N. Friedman5, A. Konkashbaev3, M. Kubo4, Y. Nakamura6, M. J. Ratain7, R. L. Benza8, N. J. Cox3, M. I. Gomberg-Maitland1, M. L. Maitland2. 1Inova Heart and Vascular Institute, Falls Church, VA, 2Center for Personalized Health, Inova Schar Cancer Institute, Falls Church, VA, 3Division of Genetic Medicine, Vanderbilt University School of Medicine, Nashville, TN, 4Center for Integrative Medical Sciences, RIKEN, Tokyo, Japan, 5Feinberg School of Medicine, Northwestern Univeristy, Chicago, IL, 6Cancer Precision Medicine Research Center, Japanese Foundation for Cancer Research, Tokyo, Japan, 7Department of Medicine, University of Chicago, Chicago, IL, 8Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA
6:30 PM	(496) Ralinepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Parameters in Patients with Pulmonary Arterial Hypertension H. W. Farber1, N. Sood2, I. R. Preston1, J. Adams3, J. Grundy3, C. King3, P. Klassen3, V. F. Tapson4, V. McLaughlin5, R. J. Oudiz6. 1Professor of Medicine, Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA, 2University of Texas Health Science Center of Houston, Houston, TX, 3Arena Pharmaceuticals, Inc, San Diego, CA, 4Cedars-Sinai Medical Center, Los Angeles, CA, 5Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine, Director of Pulmonary Hypertension Program, University of Michigan, Ann Arbor, MI, 6Department of Medicine, Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrence, CA
6:35 PM	(497) The Effects of Inhaled Sodium Nitrite on Pulmonary Vascular Impedance in Patients with Pulmonary Hypertension Associated with HFpEF M. J. Bashline1, T. N. Bachman2, N. L. Helbling3, M. T. Gladwin4, M. A. Simon3. 1Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Bioengineering, Uinversity of Pittsburgh, Pittsburgh, PA, 3Vascular Medicine Institute, UPMC Heart and Vascular Institute, Pittsburgh, PA, 4Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
Visit the ISHLT2019 Online Program Viewer to see the full abstracts from this session (Heart Transplantation)
6:40 PM	(498) Association between Serial Measurements of Tricuspid Annular Plane Systolic Excursion and Mortality Post Heart Transplant J. K. Vishram-Nielsen1, F. Foroutan2, H. J. Ross2, F. Gustafsson3, T. A. Buchan2, A. Alba2. 1The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, & Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, 2Ted Rogers Center for Heart Research, UHN, Toronto, ON, Canada, 3The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen, Denmark
6:45 PM	(499) Prognostic Value of Cardiac Magnetic Resonance Acquired at One Year after Heart Transplantation P. Patrizia1, O. Rimoldi2, G. Masciocco1, L. D'Angelo1, G. Foti1, G. Quattrocchi1, A. Milazzo1, R. Facchetti3, C. Giannattasio1, F. Maria1. 1Cardiothoracic and Vascular DPT, ASST Niguarda, Milan, Italy, 2CNR, IBFM, Segrate (MI), Italy, 3Health Science DPT, Bicocca University, Milan, Italy
6:50 PM	(500) Can CT Measures of Thoracic Muscle Provide Prognostication among Heart Transplant Recipients? A. J. Kuchnia1, J. Lortie1, N. Stabo2, N. Tsuchiya2, T. Hess3, N. Binkley3, C. Francois2, M. Schiebler2, J. Hermsen4, R. Dhingra3. 1Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, 2Department of Radiology, University of Wisconsin-Madison, Madison, WI, 3Department of Medicine, University of Wisconsin-Madison, Madison, WI, 4Department of Surgery, University of Wisconsin-Madison, Madison, WI